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Summary 
Liquid chromatography coupled with mass spectrometry is one of the most powerful tools 
in the toxicologist’s arsenal to detect a wide variety of compounds from many different 
matrices. However, the huge number of potentially abused substances and new substances 
especially designed as intoxicants poses a problem in a forensic toxicology setting. Most 
methods are targeted and designed to cover a very specific drug or group of drugs while 
many other substances remain undetected. 
High resolution mass spectrometry, more specifically time-of-flight mass spectrometry, 
represents an extremely powerful tool in analysing a multitude of compounds not only 
simultaneously but also retroactively. The data obtained through the time-of-flight 
instrument contains all compounds made available from sample extraction and 
chromatography, which can be processed at a later time with an improved library to detect 
previously unrecognised compounds without having to analyse the respective sample again. 
The aim of this project was to determine the utility and limitations of time-of-flight mass 
spectrometry as a general and easily expandable screening method. The resolution of time-
of-flight mass spectrometry allows for the separation of compounds with the same nominal 
mass but distinct exact masses without the need to separate them chromatographically. 
To simulate the wide variety of potentially encountered drugs in such a general screening 
method, seven drugs (morphine, cocaine, zolpidem, diazepam, amphetamine, MDEA and 
THC) were chosen to represent this variety in terms of mass, properties and functional 
groups. 
Consequently, several liquid-liquid and solid phase extractions were applied to urine 
samples to determine the most general suitable and unspecific extraction. Chromatography 
was optimised by investigating the parameters pH, concentration and gradient of the mobile 
phase to improve data obtained by the time-of-flight instrument. The resulting method was 
validated as a qualitative confirmation/identification method. 
Data processing was automated using the software TargetAnalysis, which provides excellent 
analyte recognition according to retention time, exact mass and isotope pattern. The 
recognition of isotope patterns allows excellent recognition of analytes even in interference 
rich mass spectra and proved to be a good positive indicator. 
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Finally, the validated method was applied to samples received from the A&E Department of 
Glasgow Royal Infirmary in suspected drug abuse cases and samples received from the 
Scottish Prison Service, which were received from their own prevalence study targeting 
drugs of abuse in the prison population. The obtained data was processed with a library 
established in the course of this work. 
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 Introduction 
Toxicology (from the Greek “toxicos” = poisonous and “logos” = word, reason – which is 
also the root of the English word logic) is the study of adverse effects of chemicals, with the 
recent addition of effects, such as noise and radiation, on a living organism and combines, 
among others, aspects of chemistry, biology and medicine. The first formalisation of 
toxicology as a science is attributed to Mathieu Joseph Bonaventure Orfila (1787–1853), 
who worked to make chemical analysis a routine part of medical forensic investigations, and 
his work Traité des poisons tirés des règnes minéral, végétal et animal; ou, Toxicologie 
générale (1812). 
Forensic Toxicology is the study of the chemical composition, preparation and identification 
of alcohol, drugs (licit and illicit) and poisons. Relevant knowledge includes absorption, 
distribution and elimination characteristics in the body, as well as the response of the body 
to these substances. The most important parts of forensic toxicological analysis is the 
quantitative and qualitative determination of drugs and/or toxic compounds in the body, with 
regard, where relevant, to the potential therapeutical application and concentration of these 
substances. 
The metabolic processes by which the body eliminates drugs and/or poisons, called 
biotransformations, can change the appearance of a compound considerably and these 
metabolic pathways must be studied separately for each individual drug or poison to 
determine potential analytes. Additionally, just as the pathways may (and probably will) vary 
for each drug so do the rates at which these biotransformations occur, which in turn has an 
impact on the metabolites that can be analysed. The matter is further complicated by the fact 
that these biotransformations can sometimes be responsible for the desired effects and/or 
toxicity of the administered substance – subsequently it should be mentioned that some 
substances, primarily poisonous substances like heavy metals such as lead, are not 
metabolised at all and are either excreted unchanged or accumulate in substance specific 
tissues. 
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1.1 Terminology of Drugs 
The three most widespread labels used for drugs or substances that are used for recreational 
purposes are “Legal High”, Designer Drug and Drug of Abuse, each of which conveys a 
certain amount of information. While these labels are not interchangeable, more than one 
may apply to a certain substance or drug and in the following a short paragraph will be 
dedicated to each label to clarify the subtle differences and how they are used in the 
literature. 
 
Definition of “Legal Highs”: Substances which mimic the effects of traditional 
drugs such as cocaine, ecstasy or marijuana while not being controlled by the 
Misuse of Drug Act are generally referred to as “Legal Highs”.  
 
The desired effects of “Legal Highs” are mostly along the lines of euphoria and 
hallucinations but the actual effects can vary significantly since most of the substances in 
this category have not been studied extensively, if they have been studied at all, or even 
undergone clinical examination. Most “Legal Highs” are either natural occurring and known 
substances – such as the proposed intoxicating effects of smoking certain herbs – used for 
recreational purposes or inappropriately used substances or drugs – such as the recreational 
use of cough syrup or anti-depressants. Furthermore, the term “Legal High” in a 
toxicological context generally refers to a new drug, whereas the novelty is more often that 
it is a variation of a known drug with intoxicating effects instead of being a novel compound, 
which is not covered by the current legislation. 
Especially new drugs, either actually novel compounds or modifications of known drugs, 
labelled as “Legal Highs” are of (forensic) toxicological interest, as the effects on the human 
body upon consumption are barely known. Even though these drugs are made with specific 
effects or parent drugs in mind to emulate its effects, which is successful in most cases, even 
simple changes on a molecule can have devastating effects on the body as the metabolic rate 
and pathways may change accordingly. The exact nature of these changes can only be 
revealed by extensive analytical and clinical studies since existing models fail to sufficiently 
predict the complex interactions between drug and metabolism. 
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Definition of Designer Drugs: “Psychotropic substances that are either 
synthetically changed natural compounds, modified molecular structures of 
existing drugs or – less commonly – completely different, designed 
chemicals”[1] 
 
The term Designer Drugs does not necessarily refer to a recent discovery of these substances 
but rather to their recent appearance on the drug market and their recent abuse. The vast 
majority of these “new” Designer Drugs are actually rooted in scientific literature which is 
widely accessible. Primarily pharmaceutical companies, but also universities and other 
research facilities, have always participated in an extensive screening of structural variations 
of existing drugs for potential pharmaceutical agents or to gain insight into the structure-
effect relationship. While these initially researched structures failed to advance to promising 
pharmaceutical agents or suitable research agents, they can be synthesised by those 
interested in them, for licit or illicit purposes, without the extensive investment into research 
of their own. 
 
Definition of Drugs of Abuse: A drug or substance is described as a Drug of 
Abuse when it is inappropriately used for recreational purposes or in a 
maladaptive pattern, which does not necessarily include dependency.  
 
While most substances that are regarded as typical Drugs of Abuse possess psychoactive 
and/or mood altering properties, the label is not limited to substances used for recreational 
purposes. Subsequently, any drug or substance that is inappropriately used, such as the use 
of steroids to enhance the physical performance in sports, is classified as a Drug of Abuse. 
While – technically – every use of a substance for something that it is not intended to be 
used for is generally regarded as being inappropriate and therefore an abuse of that 
substance, this traditional view of the black-and-white nature of either use or abuse can be 
questioned. The following model (Figure 1.1) has been proposed by A Public Health 
Approach to Drug Control in Canada (2005)[2] and allows a more diverse view on the 
matter, especially in regard to the abuse of substances. 
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Figure 1.1 A proposed model for classification of substance abuse, mainly to be used in the 
context of prevention (source: A Public Health Approach to Drug Control in Canada (2005)) 
Even though this model has certain advantages, in that it allows organising the use of 
substances according to their health and social effects, it is not universally applicable. The 
proposed instances – Beneficial Use, Casual/Non-problematic Use, Problematic Use and 
Chronic Dependency – work remarkably well for most legal intoxicants, such as alcohol, 
caffeine and nicotine, and for some drugs, such as amphetamines which are standard issue 
in some military branches due to their performance enhancing qualities or cannabis which 
has been shown to have beneficial effects in AIDS patients or cancer patients undergoing 
chemotherapy [3]. While this model could be applied to most – if not all – Drugs of Abuse, 
the inherent toxicities and/or high chances of psychological and physiological dependency 
would put those substances immediately onto the right side of the proposed spectrum. 
Additionally, the Spectrum of Psychoactive Substance Use doesn’t take legality of the 
substances and drugs in question into account and is mainly a tool designed to aim prevention 
measures more at the right side of the spectrum. 
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1.2 Challenges for Toxicological Drug Screening 
One of the challenges in forensic toxicology is the continued emergence of new drugs in the 
form of legal highs and designer drugs, as defined previously. The usage of these drugs can 
be attributed to the perceived safety of those compounds, in the case of naturally occurring 
compounds, the non-legislated status of novel compounds and the ability of especially 
designer drugs to mimic the desired effects of classical Drugs of Abuse. While legislation in 
the UK is attempting to catch up with the Psychoactive Substances Bill 2016 [4], which 
legislates drugs according to their psychoactive effects, the mimicry of desired effects makes 
these drugs of potential interest to drug users even though the side effects can be unknown 
or quite severe. This is further complicated by the fact that some of these drugs are used to 
replace classical Drugs of Abuse, as they mimic similar effects, without the knowledge of 
the user and can make self-reported drug use unreliable. 
The use of designer drugs and/or NPS has been increasingly popular in recent years and has 
grown beyond regional trends [5][6][7][8]. While the systematic abuse of these substances 
might be a recent development many if not most of these “new” drugs have been known 
scientifically beforehand but only recently appeared as drugs not scheduled for legislation. 
Concerns have been raised on the abuse of designer drugs and NPS as health professionals 
have severely limited knowledge of the effects, dangers and treatments of these substances 
[9]. This problem is further escalated as many products contain multiple active compounds 
and users may be unaware of all or any of the contents they consume [8], [10]. 
 
In order to understand the difficulties in testing these drugs it is important to understand the 
chemical structures their similarities and differences to classical drugs of abuse. The 
following is a short discussion of some of the highly substituted drug groups that are part of 
regular screening protocols but also continue to produce new designer drugs. This poses an 
analytical problem as regular users may continue to use the same group of drugs for the 
desired effects but may change, intentionally or unwittingly, to new drugs that mimic these 
effects 
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1.2.1 Amphetamines 
Amphetamine (Figure 1.2) is a heavily substituted drug, with many substitutes belonging to 
the classical Drugs of Abuse. Substitutions are generally at the hetero atom (Figure 1.3) or 
at the aromatic ring (Figure 1.4), usually position 3 and/or 4, or at both positions 
(Figure 1.5). 
 
 
Figure 1.2 Structure of amphetamine 
 
Figure 1.3 Structure of methamphetamine 
 
 
Figure 1.4 Structure of MDA 
 
 
Figure 1.5 Structure of MDEA 
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In contrast to previously discussed amphetamine derivates, para-Methoxyamphetamine 
(PMA) (Figure 1.6) and para-Methoxy-N-methylamphetamine (PMMA) (Figure 1.7) do 
not show stimulant, euphoriant or entactogen effects [11] and have been proven to be much 
more dangerous for several reasons. Firstly, PMA overdose may already occur near the usual 
recreational dose range and the actual dosage required for a potential overdose is heavily 
dependent on the user and may vary significantly [12]. Furthermore, it is often sold as other 
amphetamines with users unknowingly ingesting the considerably more dangerous PMA 
[13], with more recent cases in North Ireland and Scotland [14][15] .Structurally very 
similar, PMMA shows similar effects and dangers to PMA and death are usually linked to 
mislabelled tablets [16]. 
 
Figure 1.6 Structure of PMA 
 
 
Figure 1.7 Structure of PMMA 
 
 
1.2.2 Benzodiazepines 
Another group of drugs with a significant number of derivates are the benzodiazepines, 
which encompasses several dozen drugs and metabolites, which are a result of modification 
on the heavily modifiable benzodiazepine base structure (Figure 1.8). 
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Figure 1.8 Structure of benzodiazepine with common positions for substitutions 
 
One of the most common benzodiazepines is diazepam (Figure 1.9), which has numerous 
metabolites that are also psychoactive benzodiazepines and can be prescribed or misused 
independently. 
 
Figure 1.9 Structure of diazepam 
 
As the effects of benzodiazepines, which include sedative, anxiolytic, anticonvulsant and 
muscle relaxant, are medical relevant and continue to be researched they continue to produce 
new derivates to be potentially abused. Furthermore, the wealth of literature available on 
benzodiazepines is a constant source of compounds that were previously only of academic 
interest. One such an example is flubromazolam (Figure 1.10) which has been known in the 
literature since the early 70s [17] and has now surfaced as an abused drug [18]. 
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Figure 1.10 Structure of flubromazolam 
 
1.2.3 Synthetic Cannabinoids 
A further group with a significant number of analogues are the synthetic cannabinoids, which 
are scientifically synthesised to emulate cannabinoids, most commonly THC (Figure 1.11) 
and are of interest for the research into medicinal properties of cannabis. 
 
Figure 1.11 Structure of THC 
Notable synthetic cannabinoids are HU-210 (Figure 1.12) – a structural analogue - which is 
a potent analgesic sharing many effects as THC, but considerably stronger, and JWH-018 
(Figure 1.13) – which mimics the effects of THC - as one of the first synthetic cannabinoids 
to be under widespread legislation. 
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Figure 1.12 Structure of HU-210 
 
 
Figure 1.13 Structure of JWH-018 
 
1.3 Development of LC-MS as an analytical method and 
emergence of high resolution mass spectrometry 
The first publication of liquid chromatography coupled with mass spectrometry dates back 
to 1968 in the Russian Journal of Physical Chemistry by Victor Tal’roze. While this was 
regarded as an impressive feat, for it overcame severe difficulties in regard to injection of a 
liquid into a high vacuum, the high voltage electron impact mass spectrometer, used at the 
time, proved to be too sensitive to pressure changes. Hewlett Packard would then later 
develop the first commercially available MS interface [19] after the initial approach was 
improved upon by Baldwin and McLafferty in 1973 by introducing the liquid as a spray into 
the ionisation source. Other methods were developed around the same time by Carrol et al. 
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[20], McFadden et al. [21] and Thompson et al. [22], but the first interface that positively 
excited the LC-MS community was the Thermospray (Figure 1.14), as published by Blakley 
et al. [23]. 
 
Figure 1.14 Thermospray source design by Blakley et al. 
It was the first system capable of dealing with reversed phase solvent systems and 
compatible with LC-UV and quickly became the interface of choice. 
Techniques continued to develop and culminated finally in the simultaneous development 
of atmospheric pressure ionisation by the two researchers Henion et al. [24] and Yamashita 
et al. [25]. The first publication of the resulting interfaces was from Bruins et al. [26] and 
demonstrated sensitivity several orders of magnitude greater than other techniques at the 
time. 
These leaps in technology and application led to the launch of the first instrument – by Sciex 
in 1989 – with hardly any constraints on mobile phase composition, simple interpretation of 
spectrum data and no detectable fragmentation of proteins. This in turn opened the field for 
biochemists, drug metabolism studies and chromatographers and created the scientific field 
we see today. 
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1.4 Application of Liquid Chromatography-High 
Resolution Mass Spectrometry 
One of the most important benefits of liquid chromatography-high resolution mass 
spectrometry (LC-HRMS) is the full-scan acquisition, which allows for retrospective 
analysis and consequently does not require any prior determination of the screened analytes. 
This means that, theoretically, an unlimited number of analytes can be extracted from the 
obtained data without sacrificing sensitivity in the process. Furthermore, the resolving power 
of HRMS can help to determine the elemental composition of the analytes by means of the 
obtained exact masses and observed isotope patterns. Thus more data is obtained from high-
resolution mass spectrometry than from unit resolution data [27]. A direct comparison of the 
selectivity provided by single reaction monitoring (SRM) and HRMS coupled to liquid 
chromatography was addressed by Kaufmann et al. [28] and concluded a resolution in excess 
of 50,000 was routinely available for HRMS thus making it an attractive tool for the 
detection of trace-level amounts. The same team would later investigate the quantitative and 
confirmative performance of HRMS with >100 veterinary drugs and suggested that 
screening, quantitation and confirmation might be merged in a single step by HRMS, 
providing more flexibility, in contrast to the sequential steps necessary with conventional 
tandem mass spectrometry platforms [29]. 
Common fields of application for HRMS are food safety and environmental analysis as the 
reliable confirmation and identification can more often than not rely on trace amounts. 
Consequently, HRMS has been successfully used in the detection of adulterants in wine [30], 
[31], residues of 110 veterinary drugs in fish [32], biogenic amines in seafood [33] and 
marine biotoxin accumulation in shellfish [34]. Further studies concerning pesticides have 
demonstrated the use of HRMS to analyse the residue of 132 pesticides in agricultural 
products [35], surface residue of 240 pesticides [36] and the detection of over 500 pesticides 
in fruits/vegetables [37]. Similar studies have demonstrated the use of HRMS in the 
detection of mycotoxins in flour/bread [38], wheat & maize [39], beer [40] and other plant 
toxins in food [41]. 
The previously discussed benefits of HRMS data acquisition makes is a highly beneficial 
technique for drug discovery and has been used in quantitative bioanalysis [42], microsomal 
stability and plasma drug level measurement with additional investigation of selected drug 
metabolism via post-acquisition data mining [43]. 
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The distinct advantages of HRMS have led to numerous recent applications in the general 
screening and unknown screening of large quantities of drugs, such as Dalsgaard et al. [44] 
who established a method for 175 compounds (psychotropic, cardiovascular, designer and 
abused drugs) extracted from blood by solid phase extraction and showed limits of detection 
ranging from 5 – 50 ng/mL. Similarly, Domínguez-Romero et al. [45] established a method 
for 200 multiclass sport drugs in urine with limits of detection up to < 0.1 ng/mL, which was 
achieved by solid phase extraction and consequent filtering of the extract. The same method 
was shown to be effective in the identification of non-targeted compounds by utilising in 
source fragmentation to identify relevant metabolites. 
A method published by Marginean et al. [46] separated 23 controlled synthetic cannabinoids 
and 9 non-controlled positional isomers, extracted by protein precipitation, of JWH-018 to 
achieve a qualitative identification on HRMS data alone to be confirmed by a more 
discriminatory GC-MS technique. 
 
1.5 Drug Standards 
Standardised pure samples of drugs were used as drug reference standards to establish the 
proper methodology for analysing a particular drug, or served as a base for similar drugs 
should the desired drug be not available in its pure form, i.e. a newly emerged drug. 
Furthermore, deuterated drug standards, in which a certain number of hydrogen atoms have 
been exchanged with deuterium atoms, can be used to quantify the amount of this drug in a 
mixture as a known amount of the deuterated drug can be added to the sample without 
changing the amount of the original drug contained in the sample. 
While the method development in the following chapters did not aim towards a quantitative 
method, it was ensured that the method would work for a wide range of different compounds. 
To this end, seven compounds were chosen (Table 1.1) to represent the spectrum of 
compounds to be analysed with this method: morphine, cocaine, diazepam, zolpidem, 
amphetamine, MDEA and THC 
These drugs were chosen based on the fact that they cover a wide mass range, chemical and 
physical properties and are among the most abused drugs. While this certainly does not 
27 
 
guarantee that the method will be suitable for every drug possibly encountered, it ensures a 
wide application range necessary for general screening. 
 
 
Table 1.1 Chosen compounds to represent the desired screening range 
Structure Drugs + Formula Exact Mass 
 
 
Morphine 
C17H19NO3 
285.3377 
 
 
Cocaine 
C17H21NO4 
303.3529 
 
Diazepam 
C16H13ClN2O 
284.0716 
 
 
Zolpidem 
C19H21N3O 
307.3895 
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Amphetamine 
C9H13N 
135.2062 
 
 
 
MDEA 
C12H17NO2 
 
207.1259 
 
 
THC 
C21H30O2 
314.4617 
 
 
1.6 Calibration 
Calibration of the m/z scale of the time-of-flight mass spectrometer is achieved by external 
and internal calibration which refers to the process of calibration prior to analysis and 
simultaneously to the analysis respectively. As the calibration is essential in ensuring proper 
mass accuracy, the calibrant or reference compound should have a series of peaks, 
particularly in the mass region of interest and calibration should occur as closely as possible 
to the analysis to minimise the effects of instrument drift. 
For this work, sodium formate was chosen as a reference compound, shown in Figure 1.15, 
as it forms a series of singly or doubly charged clusters over a wide range. 
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Figure 1.15 Mass range covered by sodium formate 
External calibration is necessary as part of the preparation prior to running samples on the 
instrument and may highlight issues of maintenance. Internal calibration is achieved by 
introducing the reference compound at the beginning of the analysis where it does not 
interfere with eluting compounds and provides considerably higher accuracy. 
An example of internal calibration is shown in Figure 1.16. 
 
Figure 1.16 Blank urine sample with internal calibration peak between 0.5 minutes and 1 minute 
The mass spectrum of the internal calibration serves the same purpose as the external 
calibration, but increases the accuracy of the instrument significantly, especially when 
processing large batch numbers.  
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1.7 Aims 
The aim of this project was to develop a method for extracting and analysing a wide variety 
of drugs from urine, a primary matrix in forensic toxicology, and ultimately determining the 
utility and limitations of time-of-flight mass spectrometry as a general and easily expandable 
screening method, which includes practical and economic considerations. 
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 Method Development 
The following chapter describes the experimental methods used in the development of the 
method and the consequent results obtained. 
An overview is given over different approaches in extraction, liquid-liquid extraction and 
solid phase extraction, optimisation of mobile phase, LC conditions, relevant validation 
parameters and data processing. 
 
2.1 Materials 
DCM, IPA, NH4OH, hexane, acetonitrile, methanol, ethyl acetate and MTBE were of HPLC 
grade, sodium bicarbonate and sodium carbonate decahydrate were of analytical grade and 
were all purchased from VWR International (UK). NaOH, tris-(hydroxymethyl)-
aminomethane (TRIS), tartaric acid, glacial acetic acid, ammonium acetate, formic acid and 
HCl were of analytical grade and purchased from Sigma-Aldrich (UK). 
SPE cartridges were purchased from United Chemicals Technologies (USA) (Clean Screen 
ZSDAU020), Agilent Technologies (USA) (Bond Elut Certify) and Phenomenex (USA) 
(Strata-X-C). 
Certified drug reference standards and deuterated drug reference standards (morphine, 
cocaine, THC, MDEA, amphetamine, diazepam and zolpidem) were prepared by Cerilliant® 
(USA) and obtained from Sigma-Aldrich® (UK) in the concentrations of 1 mg/mL and 100 
µg/mL respectively. 
Synergi 4µ Fusion-RP 80Å (150 x 2.0 mm) and Gemini-C18 (4 x 2.0 mm Guard Column) 
were purchased from Phenomenex (USA). 
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2.2 Solutions 
2.2.1 1M NaOH 
4 g NaOH was dissolved carefully (exothermic reaction) in 80 mL of deionised water in a 
200 mL beaker under constant stirring. The solution was then filled up to 100 mL with 
deionised water. 
 
2.2.2 0.2M Tris Buffer 
2.44 g of tris-(hydroxymethyl)-aminomethane was dissolved in 80 mL of deionised water in 
a 200 mL beaker under constant stirring. The solution was then filled up to 100 mL with 
deionised water. The solution was stored at room temperature for up to a month. 
 
2.2.3 0.1M Phosphate Buffer pH 6 
1.7g Na2HPO4 and 12.14g NaH2PO4 were dissolved in 800 mL of deionised water and pH 
was adjusted to pH 6 with 1M KOH. The solution was then transferred into a 1 L reagent 
bottle and filled up to 1 L with deionised water. Phosphate buffer was stored at room 
temperature for up to two weeks. 
 
2.2.4 0.1M Acetic Acid 
0.576 mL glacial acetic acid were transferred into a 100 mL volumetric flask with 80 mL 
deionised water. The solution was then filled up to 100 mL with deionised water. 
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2.2.5 Hexane/Ethyl Acetate (50:50) 
For a mixture of 100 mL hexane/ethyl acetate (50:50), 50 mL of hexane were added to 50 
mL of ethyl acetate and mixed. 
 
2.2.6 DCM/IPA/NH3 (78:20:2) 
Procedure should take place in a fume hood due to the high gas pressure and intense smell 
of NH3. 20 mL of IPA were added to 78 mL of DCM in a 100 mL reagent bottle and 2 mL 
of NH3 were carefully added and the bottle closed. The mixture was then thoroughly mixed 
to ensure mixture of all components. 
 
2.2.7 Tartaric Acid (1 mg/mL) 
100 mg of tartaric acid was dissolved in 80 mL of ethyl acetate in a beaker and the solution 
was then filled up to 100 mL with ethyl acetate and stored at room temperature for up to four 
weeks. 
 
2.2.8 Acetic Acid (5% in Water) 
5 mL of glacial acetic acid are added to 80 mL of deionised water in a volumetric flask and 
the solution is then filled up to 100 mL with deionised water. The solution is stored at room 
temperature for up to four weeks. 
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2.2.9 ACN + 2 % NH4OH 
Procedure should take place in a fume hood due to the high gas pressure and intense smell 
of NH4OH. 2 mL of NH4OH were added to 80 mL of acetonitrile in a volumetric flask and 
the solution was then filled up to 100 mL with acetonitrile. 
 
2.2.10 0.1M HCl 
0.83 mL of concentrated HCl (37%) was transferred carefully into a 100 mL volumetric flask 
with 80 mL deionised water and then filled up to 100 mL with deionised water. 
2.2.11 0.1M HCl in Methanol 
0.83 mL of concentrated HCl (37%) was transferred carefully into a 100 mL volumetric flask 
with 80 mL methanol and then filled up to 100 mL with methanol. 
 
2.2.12 5 % NH4OH in Methanol 
Procedure should take place in a fume hood due to the high gas pressure and intense smell 
of NH4OH. 5 mL of NH4OH was added to 80 mL of methanol in a volumetric flask and the 
solution was then filled up to 100 mL with methanol. 
 
2.2.13 Blank Urine 
Blank urine was collected from drug-free volunteers in house, tested to make sure the 
samples were negative and stored in the fridge (4 °C). 
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2.2.14 Standard Stock Solution 
1mL of each 1 mg/mL standard solution of morphine, cocaine, zolpidem, diazepam, 
amphetamine, MDEA and THC were transferred into a 10 mL volumetric flask and filled up 
with methanol to 10 mL, which resulted in a 100 µg/mL solution for each drug.  This solution 
was stored in the freezer at -20 °C. 
 
2.2.15 Standard Working Solution (1 µg/mL) 
50 µL of the Standard Stock Solution (100 µg/mL) was transferred to a 5 mL volumetric 
flask and filled up to 5 mL with methanol, which resulted in a 1 µg/mL solution for each 
drug.  The solution was stored in the fridge at 4 °C. 
 
2.2.16 Internal Standard Working Solution (10 µg/mL) 
1mL of each 100 µg/mL standard of morphine-d3, cocaine-d3, zolpidem-d6, diazepam-d5, 
amphetamine-d5, MDEA-d5 and THC-d3 were transferred into a 10 mL volumetric flask 
and filled up with methanol to 10 mL, which resulted in a 10 µg/mL solution. The solution 
was stored in the fridge at 4 °C. 
 
2.2.17 2M Ammonium Acetate 
15.42 g of ammonium acetate was dissolved in 80 mL of deionised water under constant 
stirring and, if necessary, warming of the mixture. The solution was then filled up to its final 
volume of 100 mL with deionised water. The solution was stored at room temperature for 
up to four weeks. 
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2.2.18 0.1M Sodium Bicarbonate 
0.84 g of sodium bicarbonate was dissolved in 80 mL of deionised water under constant 
stirring and, if necessary, warming of the mixture. The solution was then filled up to its final 
volume of 100 mL with deionised water. The solution was stored at room temperature for 
up to four weeks. 
 
2.2.19 0.1M Sodium Carbonate Decahydrate 
2.86 g of sodium carbonate decahydrate was dissolved in 80 mL of deionised water under 
constant stirring and, if necessary, warming of the mixture. The solution was then filled up 
to its final volume of 100 mL with deionised water. The solution was stored at room 
temperature for up to four weeks. 
 
2.2.20 0.1 % Formic Acid and 2 mM Ammonium Acetate 
(baseline mobile phase) 
1 mL of concentrated formic acid (98 - 100%) and 1 mL of 2 M ammonium acetate was 
added to 500 mL of deionised water (aqueous buffer) or methanol (organic solvent) in a 1 L 
volumetric flask and filled up to 1 L with deionised water or methanol respectively. The 
resulting concentration was 0.1 % formic acid and 2 mM ammonium acetate and the pH of 
the aqueous buffer was determined to be pH 3. Both solutions were stored at room 
temperature for up to two weeks. 
 
2.2.21 0.007 % Formic Acid and 2 mM Ammonium Acetate 
1 mL of 2 M ammonium acetate was added to 800 mL of deionised water (aqueous buffer) 
or methanol (organic solvent) in a 1 L beaker and concentrated formic acid (98   100%) was 
added until pH 5 was measured in the aqueous solution, resulting in the addition of 77 µL of 
conc. formic acid. The solution was then transferred to a 1 L volumetric flask and filled up 
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to 1 L with deionised water or methanol respectively. The resulting concentration was 
0.007 % formic acid and 2 mM ammonium acetate. Both solutions are stored at room 
temperature for up to two weeks. 
 
2.2.22 0.0013 % Formic Acid and 2 mM Ammonium Acetate 
1 mL of 2 M ammonium acetate and was added to 800 mL of deionised water (aqueous 
buffer) or methanol (organic solvent) in a 1 L beaker and concentrated formic acid (98   
100%) was added until pH 7 was measured in the aqueous solution, resulting in the addition 
of 13 µL of conc. formic acid. The solution was then transferred to a 1 L volumetric flask 
and filled up to 1 L with deionised water or methanol respectively. The resulting 
concentration was 0.0013 % formic acid and 2 mM ammonium acetate. Both solutions were 
stored at room temperature for up to two weeks. 
 
2.2.23 Carbonate Buffer 
This buffer was prepared by adding 0.9 mL of 0.1M Sodium Bicarbonate and 1.1 mL of 
0.1M Sodium Carbonate Decahydrate to 500 mL of deionised water (aqueous buffer) or 
methanol (organic solvent) in a volumetric flask and filled up to 1 L with deionised water or 
methanol respectively. The pH of the aqueous buffer was determined to be pH 10. The 
solutions were stored at room temperature for up to two weeks. 
 
2.2.24 0.02 % formic acid and 0.4 mM Ammonium Acetate 
200 µL of concentrated formic acid (98 - 100%) and 200 µL of 2 M ammonium acetate was 
added to 500 mL of deionised water (aqueous buffer) or methanol (organic solvent) in a 1 L 
volumetric flask and filled up to 1 L with deionised water or methanol respectively. The 
resulting buffer concentrations were 0.02 % formic acid and 0.4 mM ammonium acetate and 
the pH of the aqueous buffer was determined to be pH 3. The solutions were stored at room 
temperature for up to two weeks. 
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2.2.25 0.01 % formic acid and 0.2 mM Ammonium Acetate 
100 µL of concentrated formic acid (98 - 100%) and 100 µL of 2 M ammonium acetate was 
added to 500 mL of deionised water (aqueous buffer) or methanol (organic solvent) in a 1 L 
volumetric flask and filled up to 1 L with deionised water or methanol respectively. The 
resulting buffer concentrations were 0.01 % formic acid and 0.2 mM ammonium acetate and 
the pH of the aqueous buffer was determined to be pH 3. The solutions were stored at room 
temperature for up to two weeks. 
 
2.2.26 0.001 % formic acid and 0.1 mM Ammonium Acetate 
10 µL of concentrated formic acid (98 - 100%) and 50 µL of 2 M ammonium acetate was 
added to 500 mL of deionised water (aqueous buffer) or methanol (organic solvent) in a 1 L 
volumetric flask and filled up to 1 L with deionised water or methanol respectively. The 
resulting buffer concentrations were 0.001 % formic acid and 0.1 mM ammonium acetate 
and the pH of the aqueous buffer was determined to be pH 3. The solutions were stored at 
room temperature for up to two weeks. 
 
2.2.27 0.1 % formic acid and 2 µM ammonium acetate 
1 mL of concentrated formic acid (98 - 100%) and 1 mL of 2 mM ammonium acetate was 
added to 500 mL of deionised water (aqueous buffer) or acetonitrile (organic solvent) in a 1 
L volumetric flask and filled up to 1 L with deionised water or acetonitrile respectively. The 
resulting concentrations were 0.1 % formic acid and 2 µM ammonium acetate and the pH of 
the aqueous buffer was determined to be pH 3. The solution is stored at room temperature 
for up to two weeks. 
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2.3 Instrument Parameters 
Below are shown the software versions and basic nebuliser settings used as included in the 
software package and recommended by Bruker respectively.  
 
Instrument Bruker micrOTOFq 
Software Package Compass 1.3 for micrOTOF - SR1 
Interface microTOF Control Version 3.0 (Build 53) 
  
Source ESI+ 
Nebuliser 2 Bar 
Dry Gas 8 L/min 
Dry Temp 180 °C 
Flow Rate 0.3 mL/min 
Column 
Synergi 4u Fusion-RP 80A 150 x 2.0 mm 
+ Gemini-C18 4 x 2.0 mm Guard Column 
 
Discussed are only settings which were set to deliberate values as other settings were 
dependent on the extensive calibration, done according to instrument specifications by 
qualified engineers, and were not held constant over the course of this study. 
 
2.4 Experimental 
2.4.1 Instrument Preparation 
For every change in mobile phase the instrument was prepared by flushing it with the 
respective mobile phase at 50% aqueous buffer and 50% organic solvent for several hours 
40 
 
to make sure no traces of the previously used mobile phase remained within the system and 
contaminated the results. Afterwards, the column itself was equilibrated by setting the 
mobile phase mixture to 95% aqueous buffer and 5% organic solvent and letting at least five 
column volumes of mobile phase run through it. 
 
2.4.2 Extraction Optimisation 
2.4.2.1 Liquid-Liquid Extraction 
The combination of organic solvent and aqueous buffer was optimised by investigating four 
different combinations.  For each combination the following protocol was followed.  3mL 
of organic solvent was mixed with 0.5mL of aqueous buffer and 1mL of spiked urine using 
a vortex mixer.  The sample was then centrifuged at 3000 rpm for 20 minutes to ensure phase 
separation and accumulation of matrix particles in a pellet. After phase separation the 
organic phase was extracted via a glass pipette and transferred into a 3.5 mL vial and 100 
µL tartaric acid (1mg/mL in ethyl acetate) was added to prevent more volatile compounds 
from evaporating. Consequently, the organic solvent was evaporated under a constant stream 
of nitrogen at room temperature. The extract was then reconstituted in 100 µL of mobile 
phase and transferred to a LC vial with a 250 µL insert. 
Table 2.1 below details the different solvent combinations investigated. 
Table 2.1 Organic solvent and aqueous buffer combinations investigated 
Combination Organic Solvent Aqueous Buffer 
1 Dichloromethane 1M NaOH 
2 Dichloromethane tris(hydroxymethyl)aminomethane (TRIS) 
3 tert-butyl methyl ether 1M NaOH 
4 tert-butyl methyl ether tris(hydroxymethyl)aminomethane (TRIS) 
 
The results were evaluated by determining the limits of detection for the representative group 
of drugs detailed in Section 1.5 for each combination in Table 2.1. Limits of detection have 
been determined by investigating the proposed extractions for five different concentrations 
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(4 ng/mL, 20 ng/mL, 40 ng/mL, 200 ng/mL and 400 ng/mL) achieved by spiking blank urine 
samples with the Standard Working Solution (Section 2.2.15) accordingly for a total sample 
volume of 1 mL. Additionally, 30 µL of the Internal Standard Solution (Section 2.2.16), for 
a final concentration of 300 ng/mL was added to all spiked samples after the extraction step 
to allow for the standardisation of results. 
The determined limits of detection for the tested liquid-liquid extractions are displayed in 
Table 2.2. 
Table 2.2 Limits of detection for all tested liquid-liquid extraction methods 
Compound 
Determined Limits of Detection [ng/mL] 
Combination 1 Combination 2 Combination 3 Combination 4 
Morphine 4 4 4 4 
Cocaine 40 4 400 4 
Zolpidem 4 4 4 4 
Diazepam 4 4 4 4 
Amphetamine 40 20 400 20 
MDEA 20 20 400 20 
THC 20 20 200 20 
 
Combination 2 and combination 4 showed identical results and the lowest LODs, however 
due to practical considerations combination 4 was determined to be the optimal liquid-liquid 
extraction method. 
 
2.4.2.2 Optimisation of Organic Solvent Extraction Volume 
Solvent combination 4, as detailed in Table 2.1, was determined to be the optimum solvent 
combination, therefore this was used as a starting point to optimise the solvent volumes.  The 
organic solvent volumes investigated for the extraction were 1, 2, 3 and 4 mL and followed 
the methodology described above (Section 2.4.2.1) with the respective volumes for organic 
solvent. 
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Results for the tested extraction volumes are presented in Figure 2.1 for the volumes 1, 2, 3 
and 4 mL. 
 
Figure 2.1 Peak area average of nine chromatograms of tested standards for different solvent 
volumes 
Extraction with organic solvent volumes above 3 mL yielded no higher results and thus the 
optimal volume of organic solvent used in extraction was determined to be 3 mL. 
 
2.4.2.3 Solid Phase Extraction 
Three different solid phase extraction cartridges were investigated. Three replicates at five 
different concentrations were extracted using each extraction method detailed below. 
 
2.4.2.3.1 Clean Screen Cartridge (ZSDAU020) 
0.5 mL phosphate buffer (pH = 6; 100 mM) and 4 mL deionised water were added to 1 mL 
urine and centrifuged at 3000 rpm for 10 minutes. The cartridge was conditioned with 
methanol (3 mL), deionised water (3 mL) and 100 mM phosphate buffer (pH = 6; 1 mL) 
then the sample mixture was applied to the cartridge. After the sample had been applied, the 
column was washed with deionised water (3 mL), 100 mM acetic acid (1 mL) and left to dry 
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under full vacuum for one minute before being washed with a final application of hexane (2 
mL). 
The first fraction (acidic and neutral drugs) was eluted with hexane/ethyl acetate (50:50; 3 
mL) and the cartridge washed again with methanol (3 mL) and dried under full vacuum for 
5 minutes. A second fraction (basic drugs) was eluted with DCM/IPA/NH4OH (78:20:2; 3 
mL) 
The fractions were combined and 100 µL tartaric acid solution (1mg/mL in ethyl acetate) 
was added to keep more volatile compounds from vaporising. The solvent was then dried 
under a stream of nitrogen at room temperature, reconstituted in 100 µL mobile phase and 
transferred to a LC vial with a 250 µL insert (injection volume: 10 µL). 
 
2.4.2.3.2 Bond Elut Certify 
The column was conditioned with methanol (2 mL) and equilibrated with 100 mM phosphate 
buffer (pH = 6; 2 mL). As the sample matrix was applied directly to the column without 
dilution, a positive displacement pipette was used to apply the sample (1 mL) gradually onto 
the column. Washing consisted of 5% acetic acid (1 mL), and methanol (2 mL) after which 
the sample was eluted with ACN + 2 % NH4OH (3 mL). 
100 µL tartaric acid (1mg/mL in ethyl acetate) were added to keep more volatile compounds 
from vaporising. The mixture was then dried under a stream of nitrogen, reconstituted in 
100 µL mobile phase and transferred to a LC vial with a 250 µL insert (injection volume: 
10 µL). 
 
2.4.2.3.3 Strata-X-C 
To 1mL of urine, pH 6.0, 100 mM phosphate buffer (0.5 mL) and deionised water (4 mL) 
were added before centrifuging at 3000 rpm for 10 minutes. The column was conditioned 
with methanol (1 mL) and equilibrated with pH 6.0, 100 mM phosphate buffer (2 mL), 
before the sample was applied. The column was then washed with deionised water (1 mL) 
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and subsequently 0.1M HCl (1 mL), this second wash fraction contains polar neutrals.  
Neutral and acidic compounds were washed off with 0.1M HCl in methanol (1 mL). Final 
drug elution was achieved with 5 % NH4OH in methanol (1 mL). 
The second wash fraction and elution fraction were analysed separately and 100 µL tartaric 
acid (1mg/mL in ethyl acetate) were added to each to keep more volatile compounds from 
vaporising. The mixture was then dried under a stream of nitrogen at room temperature, 
reconstituted in 100 µL mobile phase and transferred to a LC vial with a 250 µL insert 
(injection volume: 10 µL). 
The determined limits of detection for the tested solid phase extractions are displayed in 
Table 2.3 in ng/mL. 
Table 2.3 Limits of detection for all tested solid phase extraction methods 
Compound 
Determined Limits of Detection [ng/mL] 
Clean Screen Bond Elut Certify Strata-X-C 
Morphine 4 4 20 
Cocaine 4 4 4 
Zolpidem 4 4 4 
Diazepam 20 4 4 
Amphetamine 40 20 200 
MDEA 40 20 40 
THC 40 20 200 
 
As shown in Table 3.3, the best results for SPE were achieved with Bond Elut Certify 
cartridges with significantly lower limits of detection for diazepam, amphetamine, MDEA 
and THC. 
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2.4.3 Optimisation of Mobile Phase 
The conditions of the mobile phase have considerable impact in the analysis and have a 
direct impact on which compounds can be detected and the quality of the resulting data, 
therefore it is important to optimise this parameter to suit the desired method specifications. 
The following four parameters were investigated: pH of the aqueous solvent, concentration 
of the buffer, organic solvent and the gradient of the system. 
A baseline for comparison of the mobile phase has been established by using a baseline 
mobile phase, which is described in detail in Section 2.2.20. All buffers consist of a system 
of formic acid and ammonium acetate, except in the investigation of pH > 7 which utilised 
a carbonate buffer. 
 
2.4.3.1 pH 
The first parameter investigated was the pH of the aqueous buffer solution, which can 
significantly influence the separation of analytes, peak shape and overall ionisation of 
compounds. 
The original aqueous solvent of mobile phase, with a concentration of 2 mM ammonium 
acetate and 0.1% formic acid, was measured to have a pH of 3, consequently pH5, pH7 and 
pH10 were investigated for their viability in the analysis of the desired analytes. Different 
proportions of ammonium acetate and formic acid were used to achieve these different pH 
values, except for the pH 10 buffer which was a carbonate buffer system. Tests were 
performed with a sample concentration of 200 ng/mL and 3 separate samples were run in 
triplicates. 
The preparation of aqueous solvents with different pH is described in Section 2.2. 
The results for different buffer pH are presented in Figure 2.2. It should be noted that while 
for pH 7 little to no data could be acquired for Diazepam and Zolpidem - none for Cocaine, 
Morphine and THC - the measured peak areas were inconsequential in comparison to the 
significantly stronger data presented for pH 3 and pH 5 in Figure 2.3. Furthermore, no data 
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could be obtained for pH 10 as the carbonate in the solvents crystallised considerably at the 
spray shield and did not allow for data acquisition. Further investigations of the carbonate 
buffer were suspended to prevent potential damage to the instrument. 
 
Figure 2.2 Total peak area average (c = 200 ng/mL) of nine chromatograms for 
representative drugs at pH 3, 5 and 7. Results were standardised with the addition of 
deuterated internal standards 
While the change from pH 3 to pH 5 increased the response of all analysed drugs, a further 
increase to pH 7 yielded almost no results at all. However, as a pH of 7 is not conducive to 
ionisation this result is not unexpected. 
 
2.4.3.2 Buffer Concentration 
A change in the concentration of the aqueous solvent buffer, while simultaneously keeping 
a constant pH, affects the polarity and ionic strength of the mobile phase. Consequently, this 
mainly affects the peak shape but can in some cases even affect the retention of analytes on 
the stationary phase. 
Starting from the original concentration of 2 mM ammonium acetate and 0.1 % formic acid, 
several dilutions with 0.02 % formic acid and 0.4 mM ammonium acetate, 0.01 % formic 
acid and 0.2 mM ammonium acetate and 0.001 % formic acid and 0.1 mM ammonium 
acetate were investigated. Preparation of the mobile phases is detailed Section 2.2. 
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Figure 2.3 shows the results of 4 buffers. 
 
Figure 2.3 Total peak area average of nine chromatograms for representative drugs at three 
buffer concentrations 
A change from the original concentration of 0.1 % formic acid and 2 mM ammonium acetate 
to 0.02 % formic acid and 0.4 mM ammonium acetate increased the overall response of all 
drugs while a further decrease of the concentration to 0.01 % formic acid and 0.2 mM 
ammonium acetate did only yield a slight increase in the response over the original 
concentration. Further reduction of the concentration to 0.001 % formic acid and 0.1 mM 
ammonium acetate resulted in a significant drop in the overall response of all drugs. 
 
2.4.3.3 Gradient 
The percentage of the stronger solvent - methanol or acetonitrile in this case - is in reverse 
phase chromatographic methods gradually increased to reduce the overall retention window, 
reduce peak tailing and increase peak sharpness. While a gradient program can be of 
considerable complexity, including sudden steps, which increase the percentage of the 
organic solvent, or different slopes at different times to target or create certain retention 
windows, the investigated gradients have been kept fairly simple to accommodate a wide 
variety of expected and unexpected analytes. 
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Three gradient variations were investigated. Firstly, a simple linear gradient (Gradient A) 
from 95% aqueous solvent to 5% aqueous solvent over 27.5 minutes as presented in Figure 
2.4. The decreasing gradient was followed by an immediate return to 95% aqueous solvent 
over 0.5 minutes and a three-minute isocratic plateau to re-equilibrate the column for the 
next sample. 
 
Figure 2.4 Intervals and display of the linear Gradient A 
The second tested gradient (Gradient B shown in Figure 2.5) included a very steep step from 
95% aqueous solvent to 55% aqueous solvent in one minute and a consecutive slower decline 
from 55% aqueous solvent to 5% aqueous solvent over 23.5 minutes. This gradient was 
paced in that way as almost all of the desired analytes eluted when the gradient had reached 
a higher percentage of organic solvent. Consequently, Gradient B favoured the elution of 
these analytes as it shifts the focus of elution from 45% organic solvent to 95% organic 
solvent over the same time frame as Gradient A. Since the slope of the Gradient has 
consequently been decreased in Gradient B, it is aimed at the prevention of having too many 
analytes co elute at the same time. While high resolution mass spectrometry can resolve a 
high amount of co eluting analytes, co elutes can contaminate the individual mass spectra 
which are an important part of identification by the software. Additionally, the initial low 
organic percentage allows the elution of analytes that are favoured by these conditions, 
however as most analytes prefer a higher organic percentage the focus was put on the organic 
elution part of the gradient. 
This was followed by a short three-minute plateau, to ensure elution of all compounds, a 
quick return to 95% aqueous solvent over 0.5 minutes and again a short plateau at 95% 
aqueous solvent over 3 minutes to re-equilibrate the column. 
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Figure 2.5 Intervals and display of the linear Gradient B 
The final tested gradient (Gradient C shown in Figure 2.6) was very similar to Gradient B 
with a significantly increased gradient from 55% aqueous solvent to 5% aqueous solvent 
over just 12 minutes in contrast to 23.5 minutes for Gradient B. The overall time was 
shortened to decrease the time necessary to analyse multiple samples in succession while 
simultaneously achieving the same quality of analyte elution as previously established. 
The mixture was again switched quickly from 5% aqueous solvent to 95% aqueous solvent 
in 0.5 minutes with an equilibration period of 6.5 minutes. The re-equilibration period is 
significantly greater in Gradient C as in previous gradients, 6.5 minutes compared to 3 
minutes respectively. 
 
Figure 2.6 Intervals and display of the linear Gradient C 
The results for gradients B and C are shown in Figure 2.7 and Figure 2.8 with the 
background (TIC) and the individual EIC’s. 
The change from gradient B (Figure 2.7) to C (Figure 2.8) did not significantly alter the 
distance between the different peaks, but succeeded in shifting the retention times into an 
earlier window. This made a shorter run time possible and allowed the analysis of more 
samples in less time. 
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Figure 2.7 Chromatogram containing morphine, cocaine, zolpidem and diazepam (from left to 
right) using MeOH as the organic component of the mobile phase and Gradient B 
 
Figure 2.8 Chromatogram containing morphine, cocaine, zolpidem and diazepam (from left to 
right) using MeOH as the organic component of the mobile phase and Gradient C 
2.5 Qualitative Confirmation/Identification Validation 
Validation is the process of performing a set of experiments that reliably estimates the 
efficacy and reliability of an analytical method or modification to a previously validated 
method. The aim of this procedure was to establish objective evidence towards the method’s 
capability of performing at set standards and to identify the limitations under normal 
operating conditions. 
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While validating a method in a forensic toxicological setting, it should be acknowledged that 
performance can vary in day-to-day analysis due to the complexity of the components 
involved. The evaluated validation parameters serve as an estimate of a method’s actual 
performance. 
 
2.5.1 Validation 
Validation of the in Section 2.4.2.1. determined method was performed according to the 
guidelines presented in Standard Practices for Method Validation in Forensic Toxicology 
Appendix D, published by the Scientific Working Group for Forensic Toxicology 
(SWGTOX)[47]. 
 
2.5.2 Selectivity 
For the analysis with high resolution mass spectrometry, the potential interference for each 
particular analyte must be determined individually to prevent the occurrence of false positive 
results in more complex and real samples. 
 To determine any selectivity issues from matrix for individual analytes, three blank 
urine samples – made up by combining blank urine from 10 different sources – were 
prepared and spiked with a single standard (c = 300 ng/mL). The spiked urine sample 
was then extracted according to the previously established method and analysed. This 
procedure was repeated for all drugs and standards used in the method. 
 The selectivity between analytes or internal standards was determined by spiking a 
blank urine sample in triplicate – made up by combining blank urine from 10 
different sources – with one analyte and internal standards (c = 300 ng/mL). The 
experiment was repeated for each analyte contained in the method and extraction was 
conducted according to the previously established protocol. 
 Furthermore, three blank urine samples – made up by combining blank urine from 
10 different sources – were spiked with internal standards and a mixture containing 
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all relevant analytes (c = 300 ng/mL) and were extracted according to the established 
method. 
Two specific issues of selectivity were identified between the chosen standards and 
respective internal standards as shown in Figure 2.9. The shown interference was between 
the pure standards cocaine-d3 and zolpidem at 13.1 min and between the pure standards 
zolpidem-d6 and THC at 14.4 min. 
 
Figure 2.9 Observed selectivity issues in the chromatograms of zolpidem (green) and THC (blue) 
by the internal standards cocaine-d3 and zolpidem-d6 respectively 
Furthermore, it has been found that a peak that was regularly recognised by the software 
according to its exact mass as AM-2201 as shown in Figure 2.10. 
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Figure 2.10 Regularly observed exact mass match (bottom) with corresponding standard peak 
(top) for AM-2201 
 
2.5.3 Matrix Effects 
Overall matrix effects were assessed by investigating the matrix effects for the chosen 
internal standards to represent the range of different substances.  
Blank urine was collected from 10 different sources and three samples from each source 
were spiked with internal standard and standard mix solution (c = 300 ng/mL) and 
consequently extracted according to the previously established method. The results were 
consequently compared with samples extracted from pure drugs (c = 300 ng/mL). 
The ionisation suppressions/enhancements have been estimated for the established method 
by investigating and comparing different sources of urine and comparison of the observed 
deviations from samples extracted from pure standards.  
 Figure 2.11 depicts the results for the individual standards, morphine, cocaine, zolpidem, 
diazepam, amphetamine MDMA and THC, which were extracted from spiked blank urine 
injected in triplicate. 
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Figure 2.11 Assessment of matrix effects 
Figure 2.11 shows the percentage the signal deviated in the matrix from the pure standard 
and while a general matrix enhancement was determined, the degree of the effect varied 
depending on the individual urine sample. THC, while also showing matrix enhancement in 
some cases, could not be detected in several samples, which would suggest heavy matrix 
suppression.  
 
2.5.4 Limits of Detection 
The limits of detection have been determined and discussed previously in Section 2.4.2.1. 
 
2.5.5 Exact Mass Library 
The software TargetAnalysis utilises a separate user-generated library which contains the 
chemical formula, name and retention time of the desired analytes.  
Each analyte and standard was analysed individually and a library was established by adding 
the chemical formulae and respective experimental retention times of the analytes into a 
comma separated value file (.csv) which takes the form of “m/z (M+H), rt, formula, name”. 
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While it allows for the addition of the exact mass of the compound, the actual value used by 
the program is calculated internally from the chemical formula and takes precedence over 
the manual entry. 
 
2.5.6 Data processing 
The processing of data is not only an integral part of any analytical method as it is designed 
to target the specifics of any method, but it also is a powerful tool in method development. 
How the obtained data is processed has an influence mainly on the quality and scope of 
results and determines the occurrence of false positive or negative results, which is of 
particular importance forensic toxicological considerations. 
The instrument accompanying software to analyse different aspects of the acquired data 
provides several tools in data extraction and processing. Several variations of data processing 
have been investigated and are presented in the following. 
TargetAnalysis processes the obtained data by generating extracted ion chromatograms 
(EIC) for every analyte contained in the library and comparing the parameters defined in the 
library to the ones obtained from the EIC. Matches are rated in regard to acceptable 
deviations defined prior to processing and the output is demonstrated in Figure 2.12. 
 
 
Figure 2.12 Result of a spiked urine sample processed with TargetAnalysis 
The resulting EIC’s generated by the software are shown overlapped and stacked in 
Figure 2.13 and individually in Figure 2.14.
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Figure 2.13 Peaks as identified by TargetAnalysis and TIC 
 
 
 
 
 
 
 
Figure 2.14 Individual extracted ion chromatogram
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2.6 Discussion & Conclusion 
2.6.1 Optimisation of Extraction 
The organic solvents used in the investigated liquid-liquid extraction are differing on a very 
practical point, their density. Experimentally this means that DCM, which is heavier than 
water, collects as the lower phase, while MTBE, which is lighter than water, collects in the 
upper phase. This is mainly of practical consideration as MTBE is far easier to extract and 
to keep free of contamination from the aqueous phase. DCM needs to be extracted through 
the aqueous phase and thus requires much more care to prevent contamination from the 
aqueous phase. Additionally, it is considerably easier to remove MTBE through vaporisation 
than DCM which makes this particular step during the extraction process less time 
consuming. 
Comparison of the liquid-liquid extraction for urine shows that the extractions with Tris 
show generally lower limits of detection with 4 ng/mL for morphine, cocaine, zolpidem and 
diazepam and 20 ng/mL for amphetamine, MDEA and THC regardless of organic solvent 
used. Extractions with sodium hydroxide show significantly higher limits of detection with 
40 ng/mL for cocaine and amphetamine with sodium hydroxide and DCM and 400 ng/mL 
for cocaine, amphetamine and MDEA and 200 ng/mL for THC with sodium hydroxide and 
MTBE. 
Investigation of solid phase extraction cartridges showed the lowest limits of detection for 
the Bond Elut Certify cartridges with 4 ng/mL for morphine, cocaine, zolpidem and 
diazepam and 20 ng/mL for amphetamine, MDEA and THC. The Clean Screen cartridges 
showed slightly higher limits of detection for diazepam with 20 ng/mL and amphetamine, 
MDEA and THC with 40 ng/mL. Significantly higher limits of detection have been found 
for the Strata-X-C cartridges with 20 ng/mL for morphine, 40 ng/mL for MDEA and 200 
ng/mL for amphetamine and THC. 
Investigation of the organic solvent volume needed to make optimal use of the liquid-liquid 
extraction (Figure 2.1) showed 3 mL of organic solvent to be the most effective volume. 
Even though a higher volume of organic solvent (4 mL) has been tested it did not increase 
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the performance of the extraction as it showed the same results as with 3 mL of organic 
solvent. 
Matrix effects have been determined not for every drug contained in the library, but for the 
seven representative drugs to allow a general assessment of matrix effects in the established 
method for a wide variety of drugs differing in mass, retention time, solubility and chemical 
properties. Furthermore, the assessment of matrix effects for each drug contained in the 
library was considered to be economically unfeasible. 
Consequently, for the extraction of urine case samples the extraction with MTBE and Tris 
was chosen. Extractions with Tris showed in general a cleaner chromatogram as extractions 
with NaOH, as the background noise and TIC (Total Ion Chromatogram) were significantly 
lower in extractions using Tris. Furthermore, the variability between samples and injections 
has been assessed for both extractions utilising Tris to determine any significant difference 
in the %CV between both extractions. Both extraction variants, using DCM or MTBE with 
Tris, proved to be extremely close together with average %CV between different injection 
of the same extraction of 5.8 % and 6.1 % for morphine, 14.2 % and 12.4 % for amphetamine, 
4.5 % and 4.3 % for MDEA, 7.2 % and 6.1 % for cocaine, 4.7 % and 5.3 % for zolpidem, 
5.4 % and 4.1 % for diazepam and 20.4 % and 17.7 % for THC respectively. %CV values 
between samples were overall higher, but similarly close for extraction with DCM or MTBE 
with 14.6 % and 13.9 % for morphine, 32.9 % and 32.1 % for amphetamine, 15.8 % and 
16.3 % for MDEA, 11.4 % and 10.3% for cocaine, 15.1 % and 15.6 % for zolpidem, 15.4 % 
and 13.2 % for diazepam and 47.5 % and 52.7% for THC respectively. While the same limits 
of detection were determined for the extraction with MTBE and Tris as for DCM and Tris, 
the considerable easier practical considerations in the extraction process provided by using 
MTBE, as discussed previously, made this method preferable. 
 
2.6.2 Mobile Phase Optimisation 
2.6.2.1 pH 
The change of the pH of the aqueous buffer solvent proved to be unsuccessful for pH 7 and 
pH 10. In the case of pH 7, it is most likely that the absence of considerable amounts of free 
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protons (H+) did not favour the ionisation of the compounds as the ion source, in positive 
ionisation mode, yields ions in the form of M+H+. Consequently, while a very limited 
amount of data could be obtained, the detected response for all seven analytes was either 
extremely low (diazepam, zolpidem) or remained entirely undetected (morphine, cocaine, 
amphetamine, MDEA and THC).  
The analysis of the pH 10 buffer, achieved by a carbonate buffer, resulted in a completely 
different problem as the carbonate salts that make up the buffer in the aqueous solvent, while 
readily dissolving during preparation, were not volatile enough and crystallised again in the 
spray chamber physically blocking this and making the acquisition of data impossible.  
The only viable tested pH values of the aqueous solvent were pH 3 and pH 5. The recorded 
response is significantly higher with the pH 5 buffer than with the pH 3 buffer for all analytes 
and therefore this pH was chosen for the final method. 
 
2.6.2.2 Buffer Concentration 
The next investigated parameter was the concentration of the aqueous solvent buffer which 
was varied from the original concentration of 0.1 % formic acid and 2 mM ammonium 
acetate to 0.02 % formic acid and 0.4 mM ammonium acetate, 0.01 % formic acid and 
0.2 mM ammonium acetate and 0.001 % formic acid and 0.1 mM ammonium acetate. The 
lowest tested concentration, 0.001 % formic acid and 0.1 mM ammonium acetate, resulted 
in very low responses from the analytes with especially low responses for amphetamine and 
THC. While 10% dilution, with 0.01 % formic acid and 0.2 mM ammonium acetate, shows 
a slight increase in response over the original concentration the 5% dilution, with 0.02 % 
formic acid and 0.4 mM ammonium acetate, showed a significant increase in response over 
the original concentration. 
Similar limits of detection were achieved by Daalsgard et al. [44] – with 5 ng/mL for 
diazepam, cocaine and zolpidem, and 50 ng/mL for different amphetamines and morphine – 
while utilising SPE extraction of blood and a mobile phase of water/ACN and formic acid. 
Good results were shown for the extraction of synthetic cannabinoids by protein 
precipitation by Marginean et al. [46], with limits of detection ranging from 7-50 ng/mL 
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while utilising a water/MeOH mobile phase with formic acid and ammonium formate. 
Dimínguez-Romero [45] has shown considerable improved limits of detection, with many 
compounds significantly below 1 ng/mL, by using solid phase extraction followed by 
filtration of the extracts of urine samples. 
 
2.6.2.3 Gradient 
Changes in the gradient have been investigated for both solvents as alternatives for the 
organic phase of the mobile phase and methanol, as seen in Figure 2.7 to Figure 2.8, suffer 
the same interference from a high background throughout the whole chromatogram with the 
same deteriorating consequences as discussed before. In contrast, methanol as the organic 
phase of the mobile phase reacted as intended to the changes in the gradient with an overall 
reduced retention time window and reduced run length which in turn saves time in analysing 
whole batches of samples. 
 
2.6.3 Validation 
2.6.3.1 Selectivity 
The main purpose of this qualitative confirmation/identification validation is to identify 
potential sources for contamination from the matrix, sample preparation and compounds 
used.  
Several issues of selectivity have been identified, the first of which was one of the isotope 
peaks of cocaine-d3 (M+H
+ = 307.1732, with the relevant isotope being M+H+ = 308.1764) 
which is close enough to zolpidem (M+H+ = 308.1757). Both signals are still separated by 
their respective retention times with 13.1 min and 14.4 min respectively, as shown in Figure 
2.15 and identifiable by the relevant mass spectra as shown in Figure 2.16. 
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Figure 2.15 Chromatogram of Cocaine-D3 and Zolpidem 
 
 
Figure 2.16 Mass spectra of Cocaine-D3 and Zolpidem 
The next identified selectivity issue is one of the isotope peaks of zolpidem-d6 
(M+H+ = 314.2134, with the relevant isotope being M+H+ = 315.2165) which is close to 
THC (M+H+ = 315.2319). Both signals are still separated by their respective retention times, 
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with 14.4 min and 21 min respectively as shown in Figure 2.17 and identifiable by the 
relevant mass spectra as shown in Figure 2.18. 
 
Figure 2.17 Chromatogram of Zolpidem-D6 and THC 
 
 
Figure 2.18 Mass spectra of Zolpidem-D6 and THC 
 
Two direct issues in regard to selectivity have been identified in the internal standards used. 
More precisely, the first isotope peaks of cocaine-d3 and zolpidem-d6 are close enough to 
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the signals of zolpidem and THC respectively to show up in their respective trace 
chromatograms. Naturally, the isotope peaks show up at the retention time of the compound 
they originate from and thus are easily distinguished from the compounds they interfere with 
as their retention times differ significantly. Furthermore, TargetAnalysis compares the 
isotope pattern of identified compounds with their theoretically determined isotope pattern 
as one parameter to establish a positive match. Consequently, isotope peaks, while appearing 
in the trace chromatograms, are not recognised as individual compound peaks of that 
compounds extracted ion chromatogram.  
 
2.6.3.2 Exact Mass Library 
Compounds are screened and identified in their respective extracted ion chromatogram (EIC) 
according to their exact masses and retention time. An additional score sigma (σ) is 
generated which compares the isotope pattern of the obtained mass spectra against the 
theoretical isotope pattern of the compound according to its chemical formula. These mass 
spectra are obtained by the software by creating extracted ion chromatograms for all 
compounds in the database and the recognition of relevant mass at the predetermined 
retention time. 
 Intensity ≥ 1000 
Since the extracted ion chromatograms of compounds acquired with high resolution 
mass spectrometry are usually almost free of noise, the determination of signal-to-
noise ratio (3:1) was deemed not feasible. While most compounds can reliably be 
acquired at as low an intensity of 500, a can go considerably lower. To avoid the 
reporting of false positive results the limit of identification was arbitrarily set to an 
intensity of 1000. 
 Peak Shape 
While a slight broadening of peaks, depending on the analyte, can be expected all 
peaks should follow a Gaussian shape as much as possible. While this is a subjective 
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criterion that requires experience with the method, the peak shapes vary between 
analysed compounds and should not be filtered by a program.  
 mSigma Score 
The mSigma (σ) score given by TargetAnalysis is the result of comparing the 
theoretically calculated isotope pattern to the identified isotope pattern. This is, 
however, not a completely reliable indicator. While a low mSigma score signals a 
positive match of the isotope pattern and is a very strong indicator of a positive result, 
a high mSigma score does not necessarily signal a negative result. Significant 
interference, background noise or co eluting compounds in the same mass range as 
the isotope pattern can cause a high mSigma score even in positive results 
 Retention Time and Mass Error 
As in every chromatographic method, the retention time and mass match of the 
potential results are the main factors in determining positive or negative results. A 
retention time window of ±0.2 minutes was determined to be a good match and the 
widest detection range set to ±0.5 minutes to ensure detection in the case of a shift in 
retention time. The acceptable mass error was set to 5 mDa. 
The identification and overall confidence in the results could be greatly increased by adding 
fragmentation of the desired analytes to the methods. However, several limitations prevented 
the establishment of a fragmentation library to support the exact mass recognition.  
Firstly, while the software allows for MRM (Multiple Reaction Monitoring), the list for 
scanned precursor ions is limited to 50 entries, which severely limits this particular approach 
as the method can be easily expanded but already includes almost twice as many analytes as 
the software allows for MRM. 
Secondly, setting a threshold to cause the fragmentation of any compound that exceed a 
minimum signal strength is inherently problematic in any method that screens a wide range 
of different compounds as the signal strength of many compounds can vary significantly 
even if they are present at the same concentration. Consequently, a threshold set too low 
would potentially trigger fragmentation for compounds that are part of the matrix, which 
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would clutter the chromatogram with undesired data, while a threshold set too high would 
potentially miss analytes of interest with an inherently low signal strength. 
Lastly, half of every second of data acquisition is used by an untargeted fragmentation 
sweep, which fragments all ions present during that time by covering a wide range of 
fragmentation energies. While this results in the fragmentation of the desired analytes, it also 
results in a significant noise of lower mass ions – as not only the desired analytes are 
fragmented, but inherent matrix compounds as well – which made the recognition of 
qualitative ions impossible.  
 
2.6.3.3 Matrix Effects 
While all determined matrix effects showed an enhancing effect, the highest matrix effects 
were determined for THC with up to 53% enhancement. However, THC also showed a %CV 
of 19% which makes the results highly variable depending on the individual urine sample.  
Matrix effects for morphine, amphetamine MDEA, cocaine, zolpidem and diazepam were 
determined between 10 and 23% enhancement with %CV’s varying from 4-14%. The 
guidelines suggest that the average ion suppression or enhancement should not exceed ±25% 
and the %CV should not exceed 15%. These limitations are only exceeded in the case of 
THC which has already been determined as a compound with limited visibility when 
analysed in the context of this method. 
 
2.7 Conclusion 
The method established in this chapter consists of a LLE with MTBE and Tris and a mobile 
phase with the buffer concentration of 0.02 % formic acid and 0.4 μM ammonium acetate. 
Furthermore, the most suitable pH of the aqueous mobile phase has been established to be pH 5, 
while the preferred organic solvent was methanol. 
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Furthermore, while the proposed method shows a notable variance in peak area depending 
on the individual sample the results were also reproducible and the use of isotope labelled 
standards ensured that results from different samples can be compared. The wide range of 
proposed drug classes encompassed in this method makes individual analyte optimisation 
impractical. However, the method proved to be viable to screen for all representative 
compounds, with limited usability for THC analysis. 
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 Case Samples 
All urine samples were analysed using the extraction method detailed in Section 2.4.2.1 and 
the data processed according to the methodology detailed in Section 2.5.6. 
For the purpose of discussion, traditionally abused drugs and typical prescription drugs are 
combined under the nomination of drugs of abuse. Furthermore, the term Novel 
Psychoactive Substances (NPS) is expanded to entail substances not included in regular 
screenings methods as well as newer compounds that are not regularly screened for, such as 
etizolam. 
Ethical approval for samples collected from Hospital A&E admissions was sought and 
granted from NHS GG&C Ethics and they deemed it as a service evaluation. Consent was 
waived for the study as this was considered a service development study as urine samples 
are sent for a toxicology screen as a standard of care and testing was carried out on samples 
already being obtained. 
With regards to the Scottish Prison Service study, ethical approval was granted from the 
West of Scotland Research Ethics Service. A copy of the letter of approval can be found in 
the appendix. 
 
 
3.1 Hospital A&E Admission Samples (Urine) 
Glasgow Royal Infirmary is a large inner city emergency department, with ~86,000 
attendances per year. During the time between 1 May 2014 and 29 July 2014, urine samples 
and data were collected by the treating clinicians, from patients who attended the department, 
according to their medical history or clinical suspicion on the ingestion of NPS. Patients 
younger than 16 were excluded from the study. 
No case history was available in five cases, the remaining 75 were made up of 54 men (aged 
17 – 55 years) and 21 women (aged 16 – 47 years). The source of referral was by ambulance 
(37), self-referral (14) and by the police (24). 
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3.1.1 Results 
A wide range of drugs were detected as shown in Table 3.1 with their respective prescription 
status. 
Table 3.1 Frequency of detected drugs and their prescription status[48] 
Drug Not prescribed (%) Prescribed (%) 
Diazepam 24 (30) 9 (11.25) 
MDMA 18 (22.5) 0 
Cocaine 16 (20) 0 
Amitriptyline 14 (17.5) 0 
6-MAM 9 (11.25) 0 
Etizolam 7 (8.75) 0 
Amphetamine/MDA 6 (7.5) 0 
Mirtazapine 6 (7.5) 3 (3.75) 
Methadone 1 (1.25) 13 (16.25) 
MDAI 4 (5) 0 
Gabapentin 3 (3.75) 0 
Methoxetamine 2 (2.5) 0 
TFMPP 2 (2.5) 0 
PMA/PMMA 2 (2.5) 0 
Methedrone 1 (1.25) 0 
Butylone 1 (1.25) 0 
Ketamine 1 (1.25) 0 
Buprenorphine 1 (1.25) 1 (1.25) 
 
The majority of detected drugs were not prescription drugs, with the exception of methadone 
which was prescribed in 13 of the detected 14 cases. Diazepam, MDMA and cocaine were 
detected most frequently, while NPS such as methoxetamine, Butylone, MDAI and 
methedrone were detected, but only infrequently. 
Figure 3.1 and Figure 3.2 show the distribution of cases where no drugs, only NPS or only 
traditionally abused drugs were detected and the frequency of poly drug use respectively. 
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Figure 3.1 Distribution of detected drugs for A&E admissions 
As shown in Figure 3.1, the majority of samples tested positive for drugs (50%) contained 
only traditionally abused drugs, while NPS were only detected in 16 (20%) of cases. 24 
samples tested negative for all drugs.  
 
 
Figure 3.2 Frequency of poly drug use in A&E admissions[48] 
The majority of drug use was determined to be single drug use with 31%, while 49% (39) 
samples showed more than one drug present. 
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Table 3.2 Drugs detected versus patient reports[48] 
Reported ingestion Toxicology results 
No history Dihydrocodeine*, citalopram*, methoxetamine,  
Cocaine Diazepam* etizolam, cocaine, methadone*, amitriptyline 
No History Lignocaine*, mirtazapine, lamotrigine*, amitriptyline, 
methadone*. MDAI, MDA 
NPS PMA, PMMA, cocaine 
No History Diazepam, codeine*, etizolam citalopram* 
Cocaine Cocaine, MDA, diazepam, MDAI, carbamazepine* 
Cocaine TFMPP, cocaine 
No history Etizolam, codeine*, 6-MAM, carbamazepine*, methoxetamine 
Diazepam, gabapentin Etizolam, gabapentin, methadone*, MDMA 
Heroin, amitriptyline Lidocaine*, 6-MAM, codeine*, butylone 
Diazepam Amitriptyline, methadone*, 6-MAM, etizolam 
Diazepam Gabapentin, carbamazepine*, etizolam, methedrone. MDMA 
Cocaine Quetiapine, MDAI, cocaine, codeine* 
No history MDAI, diazepam, fluoxetine*, dihydrocodeine 
Ecstasy TFMPP, MDMA 
No History Etizolam, methadone*, amitriptyline, diazepam* 
* indicates drugs known to be prescribed to that individual 
 
Table 3.2 highlights the disparity between patient reports and toxicological findings, 
however it is unknown if this is intentional or if the patients were unaware of their 
consumption. 
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3.1.2 Discussion 
Of particular interest were the 24 samples which tested negative despite the specific patient 
selection for this study which targets cases with a history of drug of abuse or self-reported 
drug consumption. The negative results may be due to the concentration being too low as 
the analyte may not have been passed into the urine by the time of collection or the urine 
present concentration was below the limits of detection. Another possibility is that the 
analyte was not in the library and thus not detected, which could be remedied by processing 
the obtained high resolution data again with an expanded library – a distinct advantage of 
the data obtained by time-of-flight instrument. 
The positive results as shown in Table 3.2 show diazepam, MDMA, cocaine and 
amitriptyline as the mainly abused substances, which, with the exception of amitriptyline, 
corresponds to drugs listed in Drug-related deaths in Scotland in 2014 (© Crown copyright. 
Data supplied by National Records of Scotland) as drugs regularly involved in drug-related 
deaths. The abuse of amitriptyline is known in patients on methadone therapy [49], however 
only one patient reported the consumption of amitriptyline. 
Mirtazapine and etizolam have both been detected in significant quantities, even though none 
of the patients reported intentional consumption and the abuse of mirtazapine is not 
referenced in the literature. In the case of etizolam, only one person had a history of 
benzodiazepines consumption and etizolam was detected in combination with other illicit 
drugs present in all samples. Furthermore, etizolam and MDAI, which was detected in 4 
samples, are not currently regulated by the Misuse of Drugs Act in the UK which may 
indicate a tendency towards unregulated compounds for the purpose of abuse. 
 
3.2 Prison Prevalence Samples (Urine) 
Urine samples were provided by the Scottish Prison Service in the context of their 2013 
prevalence study and were collected over the period of one month, which yielded a total of 
904 samples. Prisons included in the data acquired for this work were Perth, Corton Vale, 
Low Moss, Barlinnie, Addiewell, Edinburgh and Polmont as they were located in the central 
belt of Scotland, chosen for logistical reasons, and Greenock as they expressed a high interest 
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in our study. The Scottish Prison Service expressed interest in the study as they were 
concerned that their own regular drug tests would not recognise the full spectrum of abused 
substances, especially NPS as they are not part of their own testing regime 
Table 3.3 shows the distribution between admission and liberation as well as the total 
number of all samples analysed for this work. 
Table 3.3 Distribution of provided admission and liberation samples by individual prisons 
Prison Total Admission Liberation 
Perth 187 123 64 
Corton Vale 101 90 11 
Low Moss 118 100 18 
Barlinnie 172 106 66 
Addiewell 63 33 30 
Edinburgh 85 25 60 
Greenock 27 11 16 
Polmont 151 102 49 
Total 904 590 314 
 
3.2.1 Results 
Figure 3.3 shows the overall positive results for all admission samples analysed (n = 590) 
and Figure 3.4 shows the overall positive results for all liberation samples analysed 
(n = 314). Results were split between drugs of abuse and novel psychoactive substances as 
defined previously. Furthermore, potential metabolites are regarded as the precursor drug in 
the discussion even though the metabolites are drugs in their own right. 
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Figure 3.3 Overall positive results for all prisons for admission (n = 590) 
Most of the positive admission samples are drugs of abuse, while NPS are significantly less 
frequent. Especially Perth, Low Moss, Barlinnie and Greenock have a very high percentage 
of positive results. In the case of Greenock however, this may be due to the small sample 
size (n = 11). 
 
Figure 3.4 Overall positive results for all prisons for liberation (n=314) 
Liberation shows again a more significant occurrence for drugs of abuse, with reduced NPS 
frequency, the difference, however, is not as pronounced as with admission samples. Low 
Moss and Greenock show, similar to admission, the highest abundancy of positive results 
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together with Edinburgh. Again, the low sample volume of Greenock (n = 16) might play a 
factor in the respective percentage. 
 
3.2.2 Results for Individual Prisons 
The results for the individual prisons are presented in the following and are displayed as 
overall results, split into drugs of abuse and novel psychoactive substances as discussed at 
the beginning of this chapter. Diagrams of the complete data for each prison are presented 
in the appendix. The following highlighted drugs were common to all prisons for both 
admission and liberation and included mirtazapine, amitriptyline, diazepam, methadone, 
cocaine and DHC in drugs of abuse and benzedrone MDAI, JWH-250, etizolam, butylone 
and methoxetamine in the NPS group. Other drugs were only found in isolated cases amongst 
the 904 samples. 
 
3.2.2.1 Perth 
Figure 3.5 shows the positive results from the samples received from Perth prison and shows 
the distribution between drugs of abuse and novel psychoactive substances. 
 
Figure 3.5 General positive results for Perth prison in percent 
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While the abundance of positive results is relatively high in admission samples for drugs of 
abuse with still significant abundance for NPS, liberation samples showed significant 
reduction in these numbers. However, 25% prevent of liberation samples have been tested 
positive for drugs of abuse. 
Figure 3.6 and Figure 3.7 show the distribution of the overall most prevalent drugs of abuse 
and novel psychoactive substances, respectively, in Perth prison. 
 
 
Figure 3.6 Most overall prevalent drugs of abuse in samples provided by Perth prison 
 
Figure 3.7 Most overall prevalent novel psychoactive substances in samples provided by Perth 
prison 
Figure 3.6 and Figure 3.7 show a significantly reduced number of positive samples for 
liberation when compared to admission for drugs of abuse as well as NPS. The strongest 
reduction is apparent in diazepam, which went from 43% to only 5%, and etizolam which 
went from 6% to 1%. However, it should be noted that the sample volume for liberation 
(n = 64) is just over half that for admission (n = 123). 
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3.2.2.2 Corton Vale 
Figure 3.8 shows the positive results from the samples received from Corton Vale prison 
and shows the distribution between drugs of abuse and novel psychoactive substances. 
 
 
Figure 3.8 General positive results for Corton Vale prison in percent 
 
Corton Vale shows a similar reduction in overall positive results and drugs of abuse from 
admission to liberation as previously discussed for Perth. However, while the percentage of 
NPS detected in liberation samples (36%) is significantly higher than in admission samples 
(19%) it should be noted that the sample volume for liberation was very limited (n = 11) and 
this result may simply be an artefact of that. 
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Figure 3.9 and Figure 3.10 show the distribution of the overall most prevalent drugs of 
abuse and novel psychoactive substances, respectively, in Corton Vale prison. 
 
Figure 3.9 Most overall prevalent drugs of abuse in samples provided by Corton Vale prison 
 
Figure 3.10 Most overall prevalent novel psychoactive substances in samples provided by Corton 
Vale prison 
While the overall prevalence of drugs of abuse has decreased from admission to liberation 
samples, as seen in Figure 3.8, the percentage of the five most abundant drugs of abuse has 
actually hardly changed or even increased with the exception of diazepam which went from 
50% admission to 9% liberation. Again, the limited sample volume of liberation samples 
(n=11) may entirely be responsible for this occurrence. 
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3.2.2.3 Low Moss 
Figure 3.11 shows the positive results from the samples received from Low Moss prison 
and shows the distribution between drugs of abuse and novel psychoactive substances. 
 
Figure 3.11 General positive results for Low Moss prison in percent 
The reduction of samples positive for drugs of abuse from admission to liberation is 
comparatively minor, however when the difference in sample numbers for admission 
(n = 100) and liberation (n = 18) is taken into account the difference is substantially bigger. 
Especially the reduction for NPS positive samples from admission to liberation is even more 
pronounced when the different sample volumes are taken into consideration. 
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Figure 3.12 and Figure 3.13 show the distribution of the overall most prevalent drugs of 
abuse and novel psychoactive substances, respectively, in Low Moss prison. 
 
Figure 3.12 Most overall prevalent drugs of abuse in samples provided by Low Moss prison 
 
Figure 3.13 Most overall prevalent novel psychoactive substances in samples provided by Low 
Moss prison 
The complete lack of diazepam or DHC positives in liberation samples is a remarkable 
difference as they showed a high prevalence in admission samples with 52% and 27% 
respectively. Most remarkable in Low Moss is the complete absence of positive NPS 
samples in regard to the most prevalent NPS encountered in this study. Consequently, the 
detected NPS in Low Moss liberation samples (APB) has been very rarely identified in the 
course of this study. 
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3.2.2.4 Barlinnie 
Figure 3.14 shows the positive results from the samples received from Barlinnie prison and 
shows the distribution between drugs of abuse and novel psychoactive substances. 
 
 
Figure 3.14 General positive results for Barlinnie prison in percent 
The results from Barlinnie prison were show an expected decline in positive liberation 
samples in drugs of abuse as well as NPS. While the sample volume for liberation samples 
(n = 66) is lower than for admission samples (n = 106) the difference is not as extreme as in 
other populations. 
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Figure 3.15 and Figure 3.16 show the distribution of the overall most prevalent drugs of 
abuse and novel psychoactive substances, respectively, in Barlinnie prison. 
 
Figure 3.15 Most overall prevalent drugs of abuse in samples provided by Barlinnie prison 
 
Figure 3.16 Most overall prevalent novel psychoactive substances in samples provided by 
Barlinnie prison 
The overall results are even more pronounced when drugs of abuse and NPS are displayed 
separately, as the abundance of all drugs has been significantly reduced. 
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3.2.2.5 Addiewell 
Figure 3.17 shows the positive results from the samples received from Addiewell prison and 
shows the distribution between drugs of abuse and novel psychoactive substances. 
 
Figure 3.17 General positive results for Addiewell prison in percent 
The sample pools of admission samples and liberation samples for Addiewell are almost 
identical with 33 and 30 respectively. However, this makes the almost non-existent reduction 
in positive samples from admission to liberation even more significant. Notable as well is 
the increase in positive NPS samples in liberation when compared to admission, even though 
the actual number of positive cases only changed from 1 to 3. 
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Figure 3.18 and Figure 3.19 show the distribution of the overall most prevalent drugs of 
abuse and novel psychoactive substances, respectively, in Addiewell prison. 
 
Figure 3.18 Most overall prevalent drugs of abuse in samples provided by Addiewell prison 
 
Figure 3.19 Most overall prevalent novel psychoactive substances in samples provided by 
Addiewell prison 
The decline in positive results for drugs of abuse are, despite the significant reduction of 
diazepam from 15% to 0%, explained by less often encountered drugs such as tramadol and 
quetiapine. Most significant, however, is the increased amount of positive NPS in liberation 
samples which is due to an increased presence of benzedrone and MDAI. 
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3.2.2.6 Edinburgh 
Figure 3.20 shows the positive results from the samples received from Edinburgh prison 
and shows the distribution between drugs of abuse and novel psychoactive substances. 
 
 
Figure 3.20 General positive results for Edinburgh prison in percent 
Drugs of abuse and NPS show more positive results in liberation samples with 53% and 8% 
respectively, than in admission samples, with 40% and 4% respectively. However, as the 
sample volumes for both admission as well as liberation are comparatively small with 25 
and 60 respectively, even a very few positive samples may have a huge impact on the 
percentage values. 
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Figure 3.21 and Figure 3.22 show the distribution of the overall most prevalent drugs of 
abuse and novel psychoactive substances, respectively, in Edinburgh prison. 
 
Figure 3.21 Most overall prevalent drugs of abuse in samples provided by Edinburgh prison 
 
Figure 3.22 Most overall prevalent novel psychoactive substances in samples provided by 
Edinburgh prison 
The minor increase in NPS in positive liberation samples can be explained by an almost 
unchanged amount of benzedrone positive samples with a new population of methoxetamine 
positive samples. The increase of drugs of abuse is not due to the most prevalent drugs shown 
in Figure 3.21, but to less often encountered drugs, such as tramadol and trazadone in this 
case. 
 
 
 
 
 
20
28
12
24
0 4
12 12
0
12
0 0
Mirtazapine Amitriptyline Diazepam Methadone Codeine DHC
Drugs of Abuse [%]
Admission (n=25) Liberation (n=60)
4
0 0 0 0 0
3
0 0 0 0
3
Benzedrone MDAI JWH-250 Etizolam Butylone Methoxetamine
Novel Psychoactive Substances [%]
Admission (n=25) Liberation (n=60)
86 
 
3.2.2.7 Greenock 
Figure 3.23 shows the positive results from the samples received from Greenock prison and 
shows the distribution between drugs of abuse and novel psychoactive substances. 
 
 
Figure 3.23 General positive results for Greenock prison in percent 
While the percentage of positive results in admission as well as liberation are comparatively 
high, the sample number of both groups was extremely limited with 11 and 16 respectively. 
Consequently, even a single positive sample has a huge impact on the percentages which 
should be taken into consideration. As the sample numbers are so low it cannot be ensured 
that the results are statistically relevant. 
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Figure 3.24 and Figure 3.25 show the distribution of the overall most prevalent drugs of 
abuse and novel psychoactive substances, respectively, in Greenock prison. 
 
Figure 3.24 Most overall prevalent drugs of abuse in samples provided by Greenock prison 
 
 
Figure 3.25 Most overall prevalent novel psychoactive substances in samples provided by 
Greenock prison 
Similar to the overall results, the percentages are heavily influence by minute changes in 
positive sample amounts and consequently, it can only be said that admission and liberation 
samples show minor differences in abundancies. Interesting, however, is while MDAI and 
etizolam are only present in admission samples, benzedrone was only detected in liberation 
samples. 
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3.2.2.8 Polmont 
Figure 3.26 shows the positive results from the samples received from Polmont prison and 
shows the distribution between drugs of abuse and novel psychoactive substances. No data 
concerning admission and liberation was available for Polmont. 
 
 
Figure 3.26 General positive results for Polmont prison in percent 
Even though a significant number of samples was received from Polmont the overall 
prevalence of drugs of abuse and NPS is comparatively low with only 20% and 11% 
respectively. 
 
 
 
 
 
25
20
11
Positive Drugs of Abuse NPS
General Results [%]
n = 151
89 
 
Figure 3.27 and Figure 3.28 show the distribution of the overall most prevalent drugs of 
abuse and novel psychoactive substances, respectively, in Polmont prison. 
 
Figure 3.27 Most overall prevalent drugs of abuse in samples provided by Polmont prison 
 
 
Figure 3.28 Most overall prevalent novel psychoactive substances in samples provided by 
Polmont prison 
Most significant is the high prevalence of JWH-250 hydroxypentyl metabolite, shortened to 
JWH-250 in the diagram. 
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3.3 Discussion 
3.3.1 Prison Prevalence Study 
The overall results for each prison shown in Figure 3.3 for admission samples and 
Figure 3.4 for liberation samples show that the vast majority of detected drugs in admission 
samples are classical drugs of abuse and prescription medication, which were combined 
under the nominator Drugs of Abuse, while novel psychoactive substances (NPS) make up 
only a fraction of positive results. Liberation samples show the same tendency towards drugs 
of abuse, albeit not as pronounced as in admission samples. While this can be partly be 
attributed to the fact that significantly fewer liberation samples have been received than 
admission samples and thus the results (shown in percentages) may appear greater at first 
glance - the alternative to present the data in total numbers would present a similar problem 
in that the numbers might appear less significant than they are due to the limited amount of 
liberation samples available. Another reason for this difference in admission and liberation 
samples is most likely the measures in place to prevent inmates from access to drugs, which 
is considerably easier to accomplish for more common and better known drugs of abuse than 
for unknown NPS. 
For each prison, the five most prevalent drugs of abuse and five most prevalent NPS, 
determined by the prevalence over all samples, have been compared for admission and 
liberation separately. 
Perth and Barlinnie prison, shown in Figures 3.5 - 3.7 and Figures 3.14 - 3.16, follow the 
same pattern as discussed for the overall results for all prisons in Figures 3.3 and Figure 3.4 
for admission and liberation respectively. Drugs of abuse have been detected significantly 
more often than NPS with considerably higher rates in admission samples than in liberation 
samples, even when taking the number difference between admission (Perth: n = 123; 
Barlinnie: n = 106) and liberation (Perth: n = 64; Barlinnie: n = 66) into account. 
Corton Vale prison (Figures 3.8 - 3.10) shows a deviation from the overall trend in that 
while admission samples have again a higher prevalence of positive drug of abuse results, 
liberation samples show a higher percentage of NPS (36%) detected than drugs of abuse 
(19%). However, due to the limited sample number for liberation with only n = 11, compared 
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to admission samples with n = 90, this is most likely not a true instance of increased NPS 
usage in prison. It is worth mentioning though that the liberation samples showed the same 
percentage of positive results (36%) for drugs of abuse and NPS but again the statistical 
relevance of this result is not clear due to the limited sample pool available. 
The results from Addiewell prison (Figures 3.17 - 3.19) show an almost identical percentage 
of drugs of abuse detected in admission (35%) and liberation (33%) which is of particular 
interest as both sample pools have almost the same number of samples with n = 33 and n = 
30 respectively. This may indicate the same quantity of usage of drugs of abuse inside the 
prison as outside and a potential drug prevention behaviour in Addiewell prison. 
Additionally, while NPS are considerably rarer detected in admission as well as in liberation, 
fewer positive results have been found in admission samples than in liberation samples with 
4% and 10% respectively. 
Low Moss prison, as shown in Figures 3.11 - 3.13, shows results comparable to those 
discussed previously for Addiewell prison with a very high number of positive results for 
drugs of abuse even in liberation samples (61%) when compared to the number of positive 
results in admission samples (77%). The number of results for NPS are significantly lower 
in admission (22%) as well as in liberation (6%). While this may indicate a relative high use 
of drugs of abuse in the prison, only a small number of liberation samples (n = 18), compared 
to significantly higher number of admission samples (n = 100), was available for analysis 
which, consequently, makes a definite conclusion difficult. 
Greenock prison is of special interest as they explicitly asked to be part of this study as they 
voiced concerns over drug use in their facility. It was not part of the originally planned seven 
prisons selected as it is a smaller prison with an upper limit of nearly 300 in custody; 
compared to i.e. Barlinnie with an average of 1305 in custody. A high percentage 
(Figure 3.23) of samples tested positive for drugs of abuse and NPS in admission samples, 
with 91% and 75% respectively, as well as liberation samples, with 27% and 19% 
respectively. While the number of samples received were comparably small for admission 
(n = 11) and liberation (n = 16), the fact that admission as well as liberation show similar 
percentages for drugs of abuse as for NPS might indicate similar drug use inside the facility 
as well as outside. 
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Edinburgh prison (Figures 3.20 - 3.22) was the only instance where liberation samples tested 
positive for a higher prevalence of drugs of abuse as well as NPS in liberation samples, with 
53% and 8% respectively, than in admission samples, with 40% and 4% respectively. While 
the number of samples available for admission (n = 25) and liberation (n = 60) might 
influence the percentages to some degree, the results indicate significant drug use inside the 
facility in respect to drugs of abuse. While results for NPS showed more positive in liberation 
than in admission samples as well, their percentages are low enough (8% and 4% 
respectively) to fall behind the more significant numbers for drugs of abuse. 
Polmont prison has been evaluated differently due to the fact that even though samples for 
admission (n = 102) and liberation (n = 49) were available for the study, the process of 
freezing and thawing those samples made a significant amount of the used labels illegible. 
As it was not clear whether these now unspecified samples were original admission or 
liberation samples, all samples (n = 151) were processed without making the distinction 
between admission and liberation to avoid unintentional bias in case more samples got 
removed from one group than the other. As a consequence, the results as shown in 
Figures 3.26 - 3.28 present an expected pattern of more positive results for drugs of abuse 
(20%) than NPS (11%). However, given the total sample size (n = 151) the number of 
positive samples for drugs of abuse and NPS is comparatively low. Additionally, Polmont 
showed the only instance of significant amounts of JWH-250 hydroxypentyl metabolite, 
shortened to JWH-250 in the diagrams, of all samples screened. This finding is significant 
in that Polmont is a holding facility for young male offenders and thus represents a segment 
potentially more prone to turn to NPS in their drug use. 
Comparison of the results with the data obtained by the prevalence study conducted by the 
SPS (Appendix), from which these samples were obtained, showed some differences in both 
the amount of positive results obtained and the drugs identified by the dip tests employed by 
the SPS. 
A reason for the higher number of overall positive results in the SPS prevalence study is a 
higher number of samples tested, as not all were passed on for this study, that the developed 
method shows a comparatively low sensitivity for cannabis which was identified in 
considerable amounts by the drug dip tests. Especially samples collected at admission 
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showed a high number of cannabis positive results, while only Polmont showed any 
significant number in liberation samples.  
Further impact on the number of obtained positive identifications from this study had the 
degradation observed in the obtained samples. Initially, the consistent cooling during storage 
until pick up was not guaranteed and while they were frozen upon arrival, pick up did not 
occur daily. Consequently, considerable degradation of sample matrix was observed and it 
follows that potential drug concentrations may have suffered similar degradation before they 
could be tested. 
 
3.4 Conclusion 
The application of high performance liquid chromatography coupled with time-of-flight 
mass spectrometry proved to be essential in analysing the samples from A&E admissions as 
well as from the Scottish Prison Service as its high resolution allowed the analysis of samples 
containing a wide variety of compounds from a single extract. This is demonstrated in 
Figure 3.29 and Figure 3.30 in which 8 and 9 compounds were identified respectively, 
many of which eluted simultaneously or in close proximity. 
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Figure 3.29 A&E admission sample (#51) containing multiple compounds 
Furthermore, gabapentin was added to the library after the sample shown in Figure 3.29 had 
already been processed but the comprehensive data obtained by the time-of-flight instrument 
allowed for a simple reprocessing of the obtained data with the expanded library. 
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Figure 3.30 Sample received from the Scottish Prison Service (Greenock #9 Admission) 
The variety in chromatograms obtained by the established method is shown in Figure 3.30 
which features compounds with very strong responses, such as DHC, methadone and 
nordiazepam, and compounds with significantly lower responses such as nitrazepam, 
temazepam and etizolam. The signal marked AM-2201 was later determined to be an 
unknown compound with the same chemical formula as AM-2201, as its isotope pattern is 
recognised by the software but AM-2201 has been shown to elute earlier – as discussed 
previously. 
The utility of extracted ion chromatograms using exact mass obtained from the time-of-flight 
instrument is immensely powerful in analyte rich samples such as shown in Figure 3.31 as 
the generated chromatograms are mostly free of any background noise.  
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Figure 3.31 Sample received from the Scottish Prison Service (Greenock #9 Admission) 
Only the extracted ion chromatograms of diazepam and oxazepam show slight increase in 
background noise which does not impede the analysis of these compounds. 
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Interpretation of the obtained results and matching the positively identified drugs with 
corresponding drug use can be extremely difficult for various reasons. Metabolic rates vary 
between individual users and are mostly unknown for NPS which is further complicated by 
the fact the time between ingestion and samples acquisition is vague or unknown and may 
even give only limited information if the same or similar compounds are ingested on a 
regular basis. 
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 Conclusion 
Time-of-flight mass spectrometry proved to be a capable tool in the general qualitative 
screening of a wide range of analytes and invaluable in the capability to retroactively process 
data with an updated library.  
The established limits of detection for the liquid-liquid extraction were determined to be 
between 5-20 ng/mL for a range of known analytes and considered a suitable range for 
qualitative screening in urine. Extractions with a stronger base agent (NaOH) proved to 
result in more background noise and interference, which resulted in significantly lower limits 
of detection. Furthermore, optimisation of mobile phase conditions showed that a lower 
buffer concentration and a higher pH created more favourable ionisation conditions for the 
compounds tested.  
The true capabilities of time-of-flight mass spectrometry with the established method were 
shown when analysing the case samples received from the A&E Department of Glasgow 
Royal Infirmary, taken in cases of suspected drug abuse, and the Scottish Prison Service, 
taken in course of their own prevalence study. Established extracted ion chromatograms 
(EIC) by the data processing software TargetAnalysis were extremely effective in the 
identification of overlapping or co-eluting compounds. EIC are remarkably background free 
chromatograms, in most cases, which allows clear identification and quick recognition of 
interference. However, the mass spectra and corresponding isotope patterns are still subject 
to interference and especially compounds with nearly identical retention times and masses 
can make identification more complicated, but by no means impossible.  
The method produced variable results for amphoteric compounds such as morphine and 
THC. The effect on morphine is significant peak broadening and tailing and a changeable 
shift in retention time window, while THC shows a good peak shape and solid retention time 
but the amount detected is highly variable between samples and injections. Furthermore, 
matrix effects remain highly dependent on specific drug investigated and while these effects 
have been taken into consideration for the representative compounds, specific matrix effects 
for other, even similar, compounds were only extrapolated.  
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Furthermore, the application of the developed method to samples received from A&E 
admissions and the Scottish Prison Service detected many NPS that would not have been 
detected otherwise. In fact, in A&E admissions etizolam was frequently detected in patients who 
reported the ingestion of other drugs or no ingestion of drugs at all. While this may have been 
intentional, this may also indicate that the drug was taken unwittingly and is sold as another drug 
for example. In the samples received from the Scottish Prison Service NPS have been detected 
in the admission pools of every prison and in most of the liberation pools. While the numbers 
themselves were low, this suggests a widespread use in and outside of the prison.  
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 Further Work 
While the established method has been shown to work for urine, an adaption to blood would 
open up many analytical advantages, as blood can indicate intoxication at the time the sample 
was taken, while urine only shows past exposure. The liquid-liquid extraction shown in this 
work, could not be adapted for blood, but one of the investigated SPE extractions might 
prove just as suitable for blood as for urine. Another potential matrix, oral fluid, has not been 
investigated but the method should be easily adaptable from urine to oral fluid on a technical 
basis.  
The simplest approach, however, would be the expansion of the library and retesting already 
processed results to gain more information. This kind of application would also make a 
powerful tool for post mortem toxicology were samples are not available for an unlimited 
timeframe, if the method can be adapted to potentially heavily degraded matrixes. In fact, 
any application that has to make use with a very limited samples volume would profit greatly 
from this capability of reprocessing data already obtained.  
Another target for the instrumentation are NPS and synthetic cannabinoids, two extremely 
rapidly changing fields. While considerable adaptation of the method might be necessary to 
focus on these fields, the previously mentioned capabilities should prove very powerful in 
detecting these compounds.  
Furthermore, while extraction and mobile phase have been extensively investigated, a 
different chromatography column might offer advantages that could not be investigated in 
this work. While the scope of different potential analytes prohibits a too specialised column, 
there are many general chromatography columns available for reverse phase and normal 
phase chromatography.  
The inclusion of fragmentation into the screening procedure has been determined to be not 
suitable as the instrument and software impose limitations on the amount of compounds that 
can be scheduled for fragmentation which was exceeded by the library early on. A general 
untargeted fragmentation approach might be considered, but preliminary tests showed 
almost complete fragmentation of the precursor ion and no recognisable fragmentation 
pattern. While more advanced instrumentation or software might be able to include 
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fragmentation into the screening procedure, it might be worthwhile to outsource any needed 
fragmentation to a more specialised instrument such as a LC-QQQ with far superior 
fragmentation capabilities. 
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 Appendix 
6.1 Exact Mass Library 
Accurate Mass RT Formula Name 
258.9858 9.1  C9H10IN  5-IAI  
135.1048 8.5  C9H13N  AMP  
171.1259 8.2  C9H17NO2  Gabapentin  
255.0079 9.8  C9H7Cl2N5  Lamotrigine  
177.0790 10.2  C10H11NO2  MDAI  
179.0946 8.3  C10H13NO2  MDA  
149.1205 8.6  C10H15N  MAMP  
165.1154 8.4  C10H15NO  PMA  
199.1209 5  C10H17NO3  Ecgonine methyl ester  
230.1031 10.7  C11H13F3N2  TFMPP  
175.0997 10  C11H13NO  5-APB  
175.0997 9.5  C11H13NO  6-APB  
193.1103 8.7  C11H15NO2  MDMA  
193.1103 8.2  C11H15NO2  Methedrone  
179.1310 8.8  C11H17NO  PMMA  
221.1052 8.5  C12H15NO3  Butylone  
207.1259 9.3  C12H17NO2  MDEA  
237.0920 9.3  C13H16ClNO  Ketamine  
234.1732 9.4  C14H22N2O  Lignocaine / Lidocaine  
266.1631 7.8  C14H22N2O3  Atenolol  
347.9665 14.5  C15H10BrClN2O  Phenazepam  
320.0120 13.6  C15H10Cl2N2O2  Lorazepam  
315.0411 13.1  C15H10ClN3O3  Clonazepam  
270.0560 14.7  C15H11ClN2O  Nordiazepam  
286.0509 14.2  C15H11ClN2O2  Oxazepam  
281.0801 13.1  C15H11N3O3  Nitrazepam  
237.0790 9.1  C15H11NO2  Methoxetamine  
236.0950 12.9  C15H12N2O  Carbamazepine  
254.1055 12.3  C15H14N2O2  Licarbazepine  
233.1780 10.1  C15H23NO  3-MeO-PCE  
284.0717 15.1  C16H13ClN2O  Diazepam  
300.0666 14  C16H13ClN2O2  Temazepam  
299.0825 14.4  C16H14ClN3O  Chlordiazepoxide  
274.1237 12.2  C16H19ClN2  Chlorpheniramine  
289.1314 9.5  C16H19NO4  Benzoylecgonine  
263.1885 9.1  C16H25NO2  Tramadol  
342.0706 14.1  C17H15ClN4S  Etizolam  
283.1209 11  C17H17NO3  3-4-MDBC  
309.1340 12.9  C17H18F3NO  Fluoxetine  
318.0958 14  C17H19ClN2S  Chlorpromazine  
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265.1579 12.3  C17H19N3  Mirtazapine  
253.1467 12.1  C17H19NO  Benzedrone  
285.1365 4.8  C17H19NO3  Morphine  
284.1347 12.6  C17H20N2S  Promethazine  
255.1623 11.2  C17H21NO  Diphenhydramine  
303.1471 10.4  C17H21NO4  Cocaine  
277.2042 10.2  C17H27NO2  Venlafaxine  
267.1623 10  C18H21NO  Pipradol-3-Isomer  
299.1522 8.5  C18H21NO3  Codeine  
266.1783 17.8  C18H22N2  Desipramine  
301.1678 8.4  C18H23NO3  DHC  
317.1627 10.3  C18H23NO4  Cocaethylene  
273.2093 10.4  C18H27NO  3-MeO-PCP  
329.1427 12.3  C19H20FNO3  Paroxetine  
307.1685 13  C19H21N3O  Zolpidem  
327.1471 8.5  C19H21NO4  6-MAM  
371.1513 12.8  C19H22ClN5O  Trazodone  
314.1550 14  C19H23ClN2  Clomipramine  
281.1780 8.7  C19H23NO  Naphyrone  
324.1638 10.9  C20H21FN2O  Citalopram  
277.1831 11.3  C20H23N  Amitriptyline  
375.1401 11.4  C21H23ClFNO2  Haloperidol  
383.1668 13.1  C21H25N3O2S  Quetiapine  
309.2093 13.7  C21H27NO  Methadone  
344.1988 17.7  C21H28O4  THC-COOH  
314.2246 20  C21H30O2  THC  
351.1835 15.2  C22H25NO3  JWH-250 Hydroxypentyl metabolite  
414.1614 12.1  C22H26N2O4S  Diltiazem  
339.2198 12.2  C22H29NO2  Propoxyphene  
474.2049 14.1  C22H30N6O4S  Sildenafil  
343.1572 15.8  C23H21NO2  JWH-073 4-Hydroxybutyl metabolite  
410.2118 12.4  C23H27FN4O2  Risperidone  
359.1685 16.7  C24H22FNO  AM-2201  
375.1635 15.6  C24H22FNO2  AM-2201 4Hydroxypentyl metabolite  
357.1729 11.4  C24H23NO2  JWH-018 4-Hydroxypentyl metabolite  
357.1729 11.4  C24H23NO2  JWH-018 5-Hydroxypentyl metabolite  
349.2406 13.1  C24H31NO  Dipipanone  
413.2566 10.2  C25H35NO4  Norbuprenorphine  
454.2832 11.8  C27H38N2O4  Verapamil  
467.3036 15.6  C29H41NO4  Buprenorphine  
  
104 
 
6.2 Letter for Ethical Approval 
105 
 
6.3 Comprehensive Prison Data 
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6.4 Publications 
6.4.1 SODAS: Surveillance of Drugs of Abuse Study 
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6.4.2 Poster Abstract: TIAFT 2014 Argentinia 
Utilising Time-of-Flight Mass Spectrometry to Profile the Drug Use as Identified from 
A&E Admissions and Prisoner Populations in Scotland 
Felix Bloeck*, Hazel Torrance 
Forensic Medicine and Science, University of Glasgow, G12 8QQ Scotland 
Aims: The aim of this study was to evaluate the suitability of high resolution mass 
spectrometry (HRMS), as a general screening method including 80 drugs (benzodiazepines, 
opiates, stimulants, antihistamines, antidepressants, antipsychotic, antiepileptic, hypnotics 
and synthetic cathinones) for the assessment of the prevalence of drugs in hospital 
admissions and prisoner populations in Scotland.   
Method: A liquid-liquid extraction (MTBE/TRIS) for urine in combination with a Full Scan 
(ESI+) LC HRMS method on a Phenomenex Fusion-RP column was developed. Limits of 
detection were found to be 4 40 ng/mL, with most drugs at 20 ng/mL or lower, while 
recovery ranged between 20% (THC) and 97% (Diazepam). The impact of matrix effects 
was evaluated and ranged between 23% ion enhancement and 19% ion suppression, 
depending on the compound, most prominently THC. Compounds were identified by 
accurate mass, retention time, isotopic pattern and signal-to-noise ratio. 
Results: 75% of urine samples (n=90) from hospital admissions were positive for drugs 
included in the library. The prevalent drugs found were “classical” drugs of abuse including 
MDMA, Diazepam, Cocaine and more unusually PMA, PMMA and Etizolam. Also 
identified were prescription drugs such as Lignocaine and Amitriptyline.  904 urine samples 
from Scottish prison facilities were analysed with 37% positive results overall and with 21% 
of liberation samples (n=265) and 44% of admission samples (n=639) tested positive. The 
most commonly identified drugs were prescription drugs including Methadone, 
Amitriptyline and Benzodiazepines (Diazepam, Temazepam, etc.).   
Conclusion: HRMS allowed for the parallel identification of coeluting and isobaric 
compounds without further chromatographic separation. The results show that mainly 
"classical" drugs of abuse continue to be abused and NPS make up a minority. Further work 
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is ongoing to include synthetic cannabinoids and NPS as required in future analysis of these 
samples. 
 
Keywords: time-of-flight, general screening, drugs of abuse, NPS, hospital admissions, 
prison 
*Presenting author 
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6.4.3 Oral Presentation: UKIAFT 2014 Leicester 
Utilising Time-of-Flight Mass Spectrometry to Assess the Prevalence of Drugs in A&E 
Admissions and Prisoner Populations in Scotland 
Felix Bloeck*, Hazel Torrance 
Forensic Medicine and Science, University of Glasgow, G12 8QQ Scotland 
A comprehensive and general toxicological screen for both common and newly emerging 
drugs is a recognised first step in a toxicological sample work up. However, this proves to 
be an analytical challenge, as an extremely wide range of drugs are available, and potentially 
abused, consisting of vastly different chemical properties. Screening techniques are designed 
to target ranges of drugs or drug families at the cost of excluding more exotic or rare 
substances that might still be abused. While these techniques are constantly evolving to 
include newer and rarer substances, there can be a considerable delay between recognition 
of an abused substance and commercially available screening techniques. 
The aims of this study are to evaluate the suitability of high resolution mass spectrometry 
(Bruker micrOTOF-Q) as a general screening method and the consequent assessment of the 
prevalence of drugs in A&E admissions and prisoner populations in Scotland. The 
application of this technology offers several advantages, most notable the ability to analyse 
a multitude of drugs simultaneously and library independence. 
For this purpose, a general and unspecific liquid-liquid extraction method for urine in 
combination with liquid chromatography-high resolution mass spectrometry was developed 
and applied to samples received from a local A&E service and Scottish prison facilities. The 
screening method includes many commonly prescribed drugs, commonly abused drugs, 
synthetic cannabinoids and a range of novel psychoactive substances (NPS). 
 
Keywords: time-of-flight, general screening, drugs of abuse, synthetic cannabinoids, NPS 
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